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 Natural products have played an important role as drug leads for different 
diseases. They provide unique structural cores with diverse biological activities. 
Because of the overuse of antibiotics many pathogens have developed antibiotic-
resistance; there is an urgent and continuing need for new antibiotics.  
 Fungi are a great source for new natural products with diverse biological 
activities; fungal genomic sequence data have shown that there are more secondary 
metabolite pathways than known metabolites. To obtain new natural products, an 
efficient way is needed to access these silent biosynthetic pathways (SBPs). Currently, 
different strategies have been used to access silent biosynthetic pathways including 
culture dependent methods like One Strain Many Compound (OSMAC) and co-culture, 
and genomic-based methods including heterologous expression and promoter activation. 
All of the above methods have their limitations, which prohibit their broad usage. In our 
group we have proposed a simple and feasible method for this purpose. Epigenetic 
regulation is a process commonly used by fungi to regulate biosynthesis. Epigenetic 
processes may silence/downregulate some secondary metabolite biosynthetic pathways. 
Small molecular epigenetic modifiers can inhibit epigenetic targets and upregulate gene 
expression. In this dissertation I have applied this strategy on two fungi and 
demonstrated that some secondary metabolite pathways can be activated/upregulated by 
epigenetic modifiers. Chapter 3 and chapter 4 will focus on the description of using 
small molecules epigenetic modifier (5-azacytidine) to access SBPs. Chapter 3 reports a 
significant change in the secondary metabolites excreted by an Atlantic-forest-soil-




new metabolites, atlantinones A and B accompanied by eight known compounds were 
isolated from the guttates. Chapter 4 describes the application of different culture 
methods let to the production of different secondary metabolites. Waikialoids A and B 
were isolated from static culture whereas asperonol A and B were from shaking culture. 
Chapter 5 is different from above chapters and it mainly focuses on the hybrid NRPS-
PKS gene coded metabolites, mutanobactin B-D, which are the signal regulators with 




































Chapter 1. Activation of silent biosynthetic pathway by epigenetic 
modification – an approach to combat multi-drug resistance 
This chapter has been adapted from portions of a previously published chapter.
1 
1.1 The importance of natural products  
 Natural products, also called secondary metabolites, are produced by living 
organisms and they play a variety of specific roles such as antifeedant, sex attractants, 
antibiotic agents and others
2
. Natural products have been the source of most of the 
active studied ingredients of medicines
3
.  By 1990 about 80% of drugs were either from 
natural products or their analogs
4
. In 1991, almost half of the best-selling drugs were 
from natural products or their derivatives 
5
. Between 1991 and 2006, 34% of all small-
molecule drugs were from natural products or their direct semisynthetic 
derivatives
6
, >75% of approved antibacterials are natural products or their semisynthetic 
derivatives
6
; furthermore, almost 50% of new anticancer drugs were natural products or 
their derivatives between 2000 and 2006
7
.  
1.2 The need and resources for new antibiotics 
Since penicillin was discovered and used as an effective antibiotic in 1940 more 
and more antibiotics have been discovered
8
. However, because of the overuse of 
antibiotics, pathogens have developed drug resistance. There are different resistances 
developed in bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus faecium 
9
 and fluoroquinolone-resistant 
Pseudomonas aeruginosa
10
. Antibiotics resistances are rapidly increasing in US 
hospitals and the development of new treatments is rather slow
11




The situation even gets worse because big pharmaceutical companies have withdrawn 
their interest in natural product antibiotics research. The need for new antibiotics is 
urgent to combat new multi-drug resistant bacteria. Microorganisms are ideal natural 
products providers because they live in complex ecosystems where they compete and 
communicate with other organisms
12
.  Among them fungi will be a major natural 
products provider because their ability to produce prolific drug candidates. A total of 
1,500 fungal metabolites were examined between 1993 and 2001 and more than half of 
them showed antibacterial, antifungal or antitumour activity.
13
 Furthermore, only a 
small portion of fungi have been cultured in the laboratory
14
. As a result fungal 
secondary metabolites are underexplored and will be a great source for finding new 
antibiotics. 
1.3 Triggering silent biosynthetic pathway in fungi 
Whole genome sequence data for fungi have shown that fungal secondary 
metabolite genes far outnumber the known metabolites
15
, the concept of silent of 
biosynthetic pathways (SBPs) was used to describe this situation that many 
microorganisms express only a fraction of their secondary-metabolite-encoding 
pathways under typical laboratory culture conditions. To access silent biosynthetic 
pathways (SBP), different methods are needed.  
1.3.1 Manipulation of culture condition 
One of the traditional, but effective methods is manipulating culture conditions. 
This method has been used for decades but was first systemically proposed by Bode in 
2002 as the OSMAC approach (One Strain–MAny Compounds) 
16
. It has been 




significantly alter secondary metabolite production. Some successful examples of 
varying this technique are summarized in Table 1.1 
Table 1.1. Examples of culture manipulation techniques. 
Organisms Elicitation Compounds Reference 
Aspergillus ochraceus 
Variation of media composition, 
vessel, and oxygenation 
Total of 15 compounds produced 





Switch from solid to liquid 
medium 






Carbon source of media  
varied 
Dankasterones A and B; 





Changing from tap H2O to 
distilled H2O 
Cytosporones 





Addition of jasplakinolide (F-
actin inhibitor)  



















10 media types with and without 
shaking 





One prime example of OSMAC is the fungus Sphaeropsidales sp. F-24'707 
which altered its metabolite profile in response to changes in media, cultivation vessels, 
solid versus liquid fermentation technique, and enzyme inhibitors. Nineteen new and 
known spirobisnaphthalene, bisnaphthalene, naphthoquinone, and macrolide 







Figure 1.1 Compounds obtained from Spha eropsidales sp. F-24'707 using culture manipulation. 
Other typical examples of OSMAC are cytosporones F−I from 
Paraphaeosphaeria quadriseptata 
18
, daldinin A-C from Daldinia concentric 
24
; 
ascospiroketals A and B from Ascochyta salicorniae 
25
; chaetoglobosins 510, 540, and 
542 from Phomopsis asparagi 
20
; and dankasterones A and B from Gymnacella 
dankaliensis 
26
, all of which responded to culture manipulation strategies by providing 
higher yields or inducing the expression of new natural products (Figure 1.2). 
Static culture with 
glucose,oatmeal, and 
degreased soy meal 
Static cultures
with oat grains
Shaking culture with 
glucose, oatmeal, and 
degreased soy meal in 
baffled flask
Shaking culture with glucose,oatmeal
,and degreased soy meal in baffled flask;












Figure 1.2 Examples of natural products obtained by manipulating microbial culture conditions 
Besides culture manipulation another strategy is the co-culture method. The 
rationale behind this method is that microbes live in complex communities with close 
relationships such as competitive, symbiotic interactions, etc. and mimicking those 
kinds of interactions in the laboratory might serve as eliciting agents for the production 
of natural products 
27
.  Based on this strategy, some agents may able to trigger SBP 
making co-culture a promising approach for natural product production
28




For example, pestalone, a unique chlorinated benzophenone, which was isolated 
from a marine-derived Pestalotia sp. in 2001
29
, possesses potent antimicrobial activity 
against several bacterial strains. However, the yield of this compound was very low, 
when live bacteria cells (an unidentified Gram-negative bacterium strain CNJ-328) were 
added to the growing fungus the yield of this compound was significantly increased 
(Figure 1.3). Later, co-culture was applied to another fungus Libertella sp. fermented 
with CNJ-328 and the fungus Emericella sp. grown in combination with a marine 







(Figure 1.3).  Recently, the production of pyocyanin 
was described from mixed fermentations of marine-sediment-derived Pseudomonas 
aeruginosa and Enterobacter sp (Figure 1.3).
32
 They observed mixed cultures can 
produce a blue metabolite pyocyanin but neither of single isolates alone were found 
capable of generating it. They designed a series of Boyden chamber experiments, the 
authors were able to demonstrate that a small-molecule membrane-diffusible factor(s) 











Figure 1.3 Examples demonstrating the use of co-culture technique to induce the production of 
microbial natural products. 
1.3.2 Using genetic-manipulation to access the silent biosynthetic pathway 
 The rapid development of new microbiological techniques and the availability 
of whole genome sequences allow activating the SBPs by heterologous expression and 
promoter exchange
33
. Heterologous expression allows silent biosynthetic genes to be 




method was used by some groups to successfully transfer specific secondary  
metabolite genes to express the metabolite. In 2006, Muller and colleagues scanned the 
myxobacterium Sorangium cellulosum genome and found a type III PKS for which no 
corresponding secondary metabolite could be identified 
34
. In that paper, they cloned 
and transferred the type III PKS into Escherichia coli and Pseudomonas sp. They 
found that only the pseudomonad was suitable as a host for gene expression.  The 
transfected Pseudomonas sp. culture turned visibly red and HPLC profiling confirmed 
the presence of a new metabolite. The structure of the compound was determined to be 
the naphthoquinone flaviolin which is readily generated from the oxidation of its 
biosynthetic precursor product, 1, 3, 6, 8-tetrahydroxynaphthalene (Figure 1.4).   
Other groups have also employed heterologous expression for natural product 
discovery. Palmu et al. have taken the idea of silent biosynthetic pathway manipulation 
for the production of new angucycline analogs
35
.  They observed that both Streptomyces 
sp. PGA64 and Streptomyces sp. H021 shared a high homology of PKS gene cluster 
36
.  
Heterologous expression of varying portions of the gene clusters in Streptomyces 
lividans TK24 resulted in the generation of natural products gaudimycin A and B 
(Figure 1.4). More and more examples demonstrated that using heterologous expression 







Figure 1.4.  Examples of SBP-derived natural products that were identified using heterologous 
expression techniques 
Promoter activation is another genetic based technology to access SBPs.  One 
example is the enhanced production of β-lactam by using promoter activation
37
. One of 
the key enzymes during penicillin biosynthesis, δ-(L-R-aminoadipyl)-L-cysteinyl-D-
valine synthetase, is encoded by the Aspergillus nidulans gene acvA. Replacement of 
the native promoter by an inducible alcohol dehydrogenase promoter (p)alcA resulted in 
increased penicillin yield about 30-fold. More recently, Chiang and colleagues 
discovered two silent PKS gene clusters adjacent to one another in the Aspergillus 
nidulans genome 
38
. By closely exam the A. nidulans genome sequence, they found that 
a gene cluster has high homology to a citrinin biosynthesis transcriptional activator. 
They replaced the putative promoter with an inducible alcAp, resulting in the 
accumulation of two new (one major and one minor) metabolites. Purification of the 
major metabolite yielded the new polyketide asperfuranone, which is structurally 
reminiscent of the azaphilones. 
 
1.4 New directions and conclusions 
Current methods for accessing silent biosynthetic pathways have their 
limitations. OSMAC is time consuming and labor intensive. For heterologous 
expression, the specific gene for transfection and expression must be determined. 




examined for accessing the SBPs. The genomisotopic method was described by 
Gerwick et al.
39
,  they used a structure prediction approach and isotopic labeling to 
detect a targeted natural product (Figure 1.5).  Pseudomonas fluorescens Pf-5 is known 
to contain a large NRPS cluster encoding a decapeptide product.  Four of the non-
ribosomal peptides synthetase’s modules exhibit highly conserved domains that are 





HMBC NMR, researchers were able to track the incorporation of 
15
N-labeled leucine 
residues into a group of related secondary metabolites, which led to the isolation of 
orfamide A (1.56) and its related congeners. This technique explores the idea of 
accessing the SBPs and also provides an important new tool for microbial secondary  





Figure 1.5 Overview of the genomisotopic method and its application to the study of 
the orfamide gene cluster in P. fluorescens Pf-5.  
 Another method was proposed by our group which uses epigenetic modification to 
access the SBP. Several epigenetic processes occur naturally in fungi
40
. This process 
involves the modification of DNA, DNA-binding proteins and histones and leads to 
changes in chromatin structure without changing the DNA sequence
41
. Two common 
epigenetic modifications are DNA methylation and histone deactylation
41b
. Other 
epigenetic alternatives have demonstrated important functions in fungi including 
altering gene transcription
42
 and modulating transcript elongation
43
. DNA methylation 

















or silencing in fungi and other organisms
44
. The inhibition of DNA methylation and 
histone deactylation might activate/upregulate the silent biosynthetic pathways by using 
epigenetic modifying agents to induce changes in fungal secondary metabolism. Based 
on this idea we have demonstrated that treating Aspergillus niger with suberoylanilide 
hydroxamic acid (SAHA) and 5-azacytidine (5-Aza), an inhibitor for histone 
deacetylases and DNA methyltransferases, will cause the upregulation of many 
secondary metabolite genes
45
. It has provided an easy and effective tool for accessing 
the silent biosynthetic pathway. We have successfully isolated the lunalides A and B 
from Diatrype disciformis 
46
. Significant changes of secondary metabolites have been 
observed in the fungus Penicillium with two new compounds, atlantinones A and B
47
. 
For the natural product research, new methods and strategies must be devised for 
producing new and bioactive secondary metabolites from microorganisms. In this 
dissertation, I describe that epigenetic modification was applied for the production of 












Chapter 2. Hypothesis and chapter overviews 
2.1 Hypothesis 
Fungal genomic sequence information showed that there are more undiscovered 
secondary metabolites in fungi than known compounds. Epigenetic modifications are 
proposed to be an effective tool for activating silent biosynthetic pathways, leading to 
the proposal of the hypothesis: Small molecular epigenetic modifiers 
(suberoylanilide hydroxamic acid and 5-azacytidine) activate or upregulate silent 
biosynthetic pathways in fungi. This hypothesis was tested via the following specific 
aims:  
1. Isolation of new antimicrobial natural products from Penicillium citreonigrum 
collected from the Brazilian Atlantic Forest  
2. Isolation of new antimicrobial natural products from an Aspergillus. sp collected 
in Hawaii 
Chapter 3 and 4 describes the result of using epigenetic modifiers on two different fungi 
along with the discovery of new natural products. Chapter 5 is a description of hybrid 
polyketide-non-ribosomal-peptide natural products from a human oral pathogen 
Streptococcus mutans. The point of view was the same as other two projects: trying to 
find new antimicrobial drugs by using unique strategy.  
2.2 Chapter 3. Chemical Epigenetics Alters the Secondary Metabolite Composition 
of Guttate Excreted by an Atlantic-Forest-Soil-Derived Penicillium citreonigrum 
 In this project we applied the epigenetic modifier 5-azacytidine to an Atlantic-
forest-soil-derived Penicillium citreonigrum for activating biosynthetic pathway. We 




fungal exudates. While guttate from control cultures exhibited a relatively simple 
assemblage of secondary metabolites, the guttate collected from cultures treated with 50 
µM 5-azacytidine (a DNA methyltransferase inhibitor) were highly enriched in 
compounds representing at least three distinct biosynthetic families. The metabolites 
obtained from the fungus included six azaphilones (sclerotiorin, sclerotioramine, 
ochrephilone, dechloroisochromophilone III, dechloroisochromophilone IV, and 6-
((3E,5E)-5,7-dimethyl-2-methylenenona-3,5-dienyl)-2,4-dihydroxy-3-
methylbenzaldehyde), pencolide, and two new meroditerpenes (atlantinones A and B).  
While pencolide was detected in the exudates of both control and 5-azacytidine-treated 
cultures, all of the other natural products were found exclusively in the guttates of the 
epigenetically modified fungus.   
2.3 Chapter 4. Novel dimeric isoprenylated indole alkaloids isolated from 
Aspergillus sp. by manipulating the culture conditions  
This chapter mainly focuses on the isolation of new natural products by 
manipulating the culture conditions. We applied epigenetic modifiers 5-azacytidine (5-
Aza) and suberoylanilide hydroxamic acid (SAHA) to a Hawaii-soil-derived fungus. 
However, we did not observe significant secondary metabolite profile changes 
compared to that of untreated culture. We did observe a significant difference of 
secondary metabolite profiles of static cultures compared to liquid culture. Two novel 
dimeric isoprenylated indole alkaloids, waikialoid A (4.7) and B (4.8), with a unique 
bicyclo[2.2.2]diazaoctane ring, and two new metabolites, asperonol A and B, were 




on the basis of spectroscopic data. The isolated compounds were evaluated for their 
anticancer and antibiofilm activity. 
2.4 Chapter 5. New hybrid NRPS-PKS encoded cyclopeptides mutanobactins B-D 
from the human oral pathogen Streptococcus mutans. 
Streptococcus mutans is a Gram-positive pathogen that is a primary inhabitant 
of the human oral biofilm and responsible for the development of dental caries.
48
  The 
deletion of a gene cluster encoding a putative hybrid polyketide synthase-nonribosomal 
peptide synthetase (PKS-NRPS) derived metabolite in Streptococcus mutans UA159 
caused a loss of several resistance traits associated with oxygen and hydrogen peroxide 
tolerance, as well as biofilm formation.
49 
We have isolated the NRPS-PKS coded 
metabolites mutanobactin A-D and their structures have been identified on the basis of 















Chapter 3. Chemical Epigenetics Alters the Secondary Metabolite 
Composition of Guttate Excreted by an Atlantic-Forest-soil-derived 
Penicillium citreonigrum 




Our research group has been actively pursuing the development of chemical 
epigenetic methods for procuring secondary metabolites from fungi.
51
 We have 
demonstrated that this is an effective technique for promoting the transcription of silent 
biosynthetic pathways involved in the formation of polyketide, non-ribosomal peptide, 
and hybrid polyketide-non-ribosomal-peptide natural products.
52
 Moreover, we have 
shown that a chemical epigenetics approach is well suited for the generation of 
structurally unique secondary metabolites with promising drug discovery applications.
53
 
In order to maximize the opportunity for detecting novel secondary metabolites, we 
have begun using chemical epigenetic induction as a routine part of our screening 
program involving the exploration of fungi obtained from minimally explored 
environments/ecological niches (e.g., insects and littoral zones
53b
). 
Our investigation of fungi from ecologically diverse environments has recently 
expanded to include soil from the Brazilian Atlantic Forest. The Atlantic Forest is 
regarded as one of the most species-rich habitats in the world, but unfortunately, it is 







 The secondary metabolite profile (observed by HPLC) for one of the solid-state 
fungal cultures exhibited an exceptionally dramatic response to chemical epigenetic 






the fungus produced rust-red-colored droplets of exudate on its mycelial surface, 
whereas untreated (control) cultures produced colorless exudates. 
Fungal exudates, which are more formally known as guttates, are observed with 
considerable frequency in solid-state fungal cultures. Despite the widespread occurrence 
of this phenomenon, a surprisingly small number of accounts have been published 
exploring the composition of fungal guttates. The few studies that do exist suggest that 
these droplets are a rich source of primary and secondary metabolites, inorganic 
elements, and proteins/enzymes.
55
  For example, strains of Penicillium nordicum and 
Penicillium verrucosum grown for 14 days on Petri plates containing Czapek yeast agar 
were reported to have accumulated substantial amounts of guttate, which was enriched 
in ochratoxins A and B (on average, approximately 1-8 µg/mL).
55e
 Similarly, cultures of 
Metarhizium anisopliae that were reared on several different media accumulated 
destruxins A, B, and E in their exudates at levels averaging between 2-6 µg/mL.
55a
 The 
ecological significance of guttation remains uncertain although several possible 
functions have been proposed. These roles include facilitating active hyphal expansion 
under conditions of unfavorable water potential,
56
 providing a mechanism for 
transporting enzymes that are involved in host invasion and/or liberation of essential 
nutrients from substrates,
55d, 57
 and creation of unique microhabitats capable of 
supporting symbiotic bacterial communities.
58 
In light of the striking guttate coloration 
induced in the Atlantic Forest fungal isolate, we initiated this project to discern what 
changes occurred to the chemical diversity of the fungal guttate upon treatment of the 
organism with 5-azacytidine which is a DNA methyltransferase inhibitor. In this report, 




of secondary metabolite pools in the guttate produced by an Atlantic-Forest-derived 
fungal isolate. 
3.2 Result and Discussion 
The sequence of a 321 base-pair portion of the large ribosomal subunit 28S 
rRNA gene from the Atlantic-Forest-soil-derived isolate shared 100% homology with 
the sequence reported in the NCBI database for Penicillium citreonigrum Dierckx (syn. 
Eupenicillium hirayamae D. B. Scott & Stolk). Growth of the fungus on a vermiculite-
based solid-state medium containing 0, 10, 50, 100, or 200 µM 5-azacytidine showed 
that cultures exposed to ≥50 µM of the epigenetic modifier developed dark red guttates, 
which stood in vivid contrast to the colorless guttates produced by control cultures 
(Figure 3.1A and 3.1B). Gradient HPLC was used to compare the guttates from 20-day 
old control cultures versus fungal colonies treated with 50 µM 5-azacytidine. Whereas 
the control guttates were relatively devoid of small molecules, the HPLC profiles of 
guttates from 5-azacytidine-treated cultures were highly enriched in secondary 





Figure 3.1.  Guttates of solid-state P. citreonigrum cultures grown under control conditions (A) or in the 
presence of 50 µM 5-azacytidine (B).  HPLC chromatograms (C18 column using a gradient of 5-100% 
methanol in water and recorded at 210 nm) illustrating the differences between the metabolite profiles of 
the control (C) and 5-azacytidine-treated (D) P. citreonigrum guttates. Metabolites identified in scale-up 
isolation studies were used as authentic references to verify the identities of compounds 3.1-7 and 3.9 and 
3.10 in the guttates. 
Scale-up solid-state cultures of P. citreonigrum treated with 50 µM 5-azacytidine were 
prepared and after 20 days, the resulting guttate-covered mycelia were washed with 
ethyl acetate. The ethyl acetate was removed under vacuum and the remaining solid 
residue was resuspended in methanol prior to defatting with hexane.  The methanol-
soluble material was subjected to repeated C18 gradient HPLC, which yielded six 






















ionization mass spectra (HRESIMS) data facilitated the rapid dereplication of five 
azaphilones.
59





 dechloroisochromophilone III (3.3),
62
 dechloroisochromophilone 










C NMR data that were remarkably similar to the chemical shifts observed for 3.1-5.  
Interpretation of the HRESIMS (m/z of 412.1290 [M+Na]
+
 calcd for C21H24NO4ClNa, 
412.1292) and NMR data for 3.6 revealed that our metabolite matched the structure 
reported for the sclerotioramine (3.6), which had been previously obtained as a 
semisynthetic derivative of 3.1.
63
 Unfortunately, we were unable to find any NMR data 
published for this substance so we performed a thorough analysis of 3.6 using 
2-3
JH-C 
HMBC NMR spectroscopy to facilitate the assignment of its proton and carbon 
resonances. An important step in our investigation was confirming the location of the 
amine nitrogen in ring B. This was achieved by comparing the upfield changes in the 
chemical shifts for the C-1 and C-3 resonances (δC 138.4 and 146.6, respectively) in 3.6 
to the corresponding C-1 and C-3 chemical shifts surrounding the oxygen atom in 
compound 3.1 (δC 152.6 and 158.1, respectively). 
The installment of a nitrogen atom at the 2-position of compound 3.6 is quite 
remarkable since the biosynthesis of the azaphilones has been proposed to arise from a 





C sodium acetate have leant strong support for this 
hypothesis.
61, 64




cluster complex that is responsible for generating an azaphilone metabolite in 
Aspergillus nidulans has provided convincing support for the polyketide origins of this 
metabolite family.
65
 Although 3.6 has not been previously described as a natural 
product, other nitrogen-containing azaphilones have been reported from fungal 
sources.
66
 All of these vinylogous -pyridone metabolites are thought to arise from the 
substitution of a primary amine/ammonia for the azaphilone’s pyranyl oxygen atom in a 
process that is initiated by the nucleophilic attack of the nitrogen at the C-1 position.
66a
 
Therefore, we can reasonably surmise that 3.6 is formed as a consequence of 3.1 
reacting with endogenous ammonia from P. citreonigrum during the culture process.
67
 
Compound 3.7 was obtained as a colorless solid that exhibited a m/z of 218.0432 
[M+Na]
+
 by HRESIMS. This established a molecular formula of C9H9NO4 for 3.7 
(calcd for C9H9NO4Na, 218.0429), which required six units of unsaturation. Analysis of 






JH-C HSQC, and 
2-3
JH-C HMBC) led us to 
determine that the structure of 3.7 was the same as the structure that had been 
previously proposed for pencolide.
68
 Although this metabolite had been encountered on 
at least two prior occasions from Penicillium species,
68-69
 no detailed investigation 




C NMR resonances had been reported. Moreover, debate 
that had arisen concerning the C-2, C-3 double bond configuration of 3.7 had not yet 
been fully resolved.
70
 Therefore, we investigated the double bond configuration of 3.7 
by treating it with thionyl chloride in methanol, which yielded the methyl ester 
derivative 3.8. Using one-dimensional nuclear Overhauser effect difference correlation 
(1D difference NOE) spectroscopy, we observe reciprocal NOEs between the olefinic 




irradiation of the C-4 methyl protons (δH 1.77) only provided enhancement of the H-3 
resonance. These findings strongly support a Z configuration for the C-2, C-3 double 
bond in 3.7. 
 
Figure 3.2.  Correlations obtained from 
2-3
JH-C HMBC experiment that were used to generate fragments 




H ROESY correlations that 
were used to help assign the relative configuration of 3.9a (B). 
HRESIMS analysis of compound 3.9 provided a pseudomolecular ion with a m/z 
of 465.2256 [M + Na]
+
 that was consistent with a molecular formula of C26H34O6 (calcd 
for C26H34O6Na, 465.2253). This required 10 degrees of unsaturation in the metabolite.  
A survey of the 
13
C NMR data for 3.9 collected in CDCl3 (Table 3.1) confirmed the 
presence of 26 unique carbon atoms including two ketone (δC 209.6 and 211.3), two 
ester (δC 168.3 and 174.8), and two vinylic carbon (δC 127.4 and 132.0) resonances.  
This accounted for five of the 10 double-bond equivalents in 3.9, which meant that the 
remaining units of unsaturation were derived from five rings. Examination of the 
1
H 
NMR data (Table 3.1) revealed six methyl singlets (δH 1.02, 1.07, 1.32 (2), 1.69, and 
3.54; each integrated for 3H), a methyl doublet (δH 1.19, J = 6.8 Hz, 3H), a vinylic 
hydrogen singlet (δH 5.67, 1H), a doublet (δH 4.07, J = 3.9, 1H), a quartet (δH 3.20, J = 




The congestion caused by multiple resonances overlapping in the upfield region of the 
1
H NMR spectrum prompted us to explore other solvents for performing NMR 
experiments with 3.9. Turning to CD3OD, we were surprised by two significant 
qualitative changes in the 
1
H NMR spectrum (Table 3.1): the methyl doublet previously 
at δH 1.19 now appeared as a singlet (δH 1.57, 3H) and the quartet at δH 3.20 was 
missing. Upon reexamination of the 
1
JH-C HSQC data for 3.9 collected in CDCl3 we 
observed that the missing hydrogen had been bonded to a carbon resonating at δC 51.4.  
The 
13
C NMR data for 3.9 collected in CD3OD (Table 3.1) exhibited other substantial 
changes that included both the loss of a ketone resonance (δC 211.3) and the carbon at 
δC 51.4. In place of the missing carbon spins, we observed two new vinylic carbon 
resonances appearing at δC 113.7 and 192.1. The substantial downfield shift of the 
vinylic carbon at δC 192.1 suggested that it was attached to an oxygen atom. The 
2-3
JH-C 
HMBC data for 3.9 in CD3OD revealed that the protons of the methyl singlet at δH 1.57 
coupled not only with both of the vinylic carbons, but also exhibited a correlation to a 
ketone resonance at δC 201.8 (Figure 3.2A, fragment A). This led us to deduce that 
compound 3.9 possessed a tautomerizable substructure that existed in its keto-enol form 
in CD3OD (3.9a) and rearranged into a β-diketone in CDCl3 (3.9b) (Figure 3.3). We 
confirmed this by removing 3.9 from the CD3OD and resuspending the compound in 




C NMR and HRESIMS data for the metabolite that were 





Figure 3.3.  Possible tautomers proposed for 
compound 3.9.  The enol-keto structure 3.9a 
(upper left) was the only tautomer observed in 
methanol; while the β-diketone compound 3.9b 
(lower center) was exclusively seen in 
chloroform.  The alternative enol-keto form of 
3.9 (upper right) was not detected by NMR 
under these experimental conditions. 
Having established the tautomeric portion of the new metabolite (Figure 3.2A, 
fragment A), we focused our attention on determining the remaining structural elements 




C NMR resonances associated with the rest of 
the metabolite in 3.9a and 3.9b appeared very similar to one another (Table 3.1).  
Therefore, we concentrated on using the 2D NMR dataset collected for 3.9a as the basis 
for resolving the rest of this compound’s structure.  Examination of the 
2-3
JH-C HMBC 
data for 3.9a enabled us to construct four additional substructures for the metabolite 
(Figure 3.2A, fragments B-E). 
The development of fragment B (Figure 3.2A) was largely facilitated by the 
fortuitous proximity of three methyl groups and one olefinic proton, which provided a 
nearly exhaustive set of overlapping 
2-3
JH-C HMBC correlations among the 
substructure’s nine carbon atoms. The first methyl singlet (δH 1.36) exhibited a series of 
three couplings with carbon resonances at δC 43.0, 47.6, 69.8. The second methyl 
singlet (δH 1.22) was also correlated to the carbon at δC 69.8, as well as carbons at δC 
57.5 and 134.7. The third methyl singlet (δH 1.82) shared two of the same correlations 




the olefinic singlet proton (δH 5.44) was coupled to a methyl carbon (δC 20.3) and 
carbons at δC 43.0 and 57.5. The combination of these overlapping 
2-3
JH-C couplings 
enabled us to deduce that fragment B constituted a highly substituted cyclohexene 
system (Figure 3.2A, fragment B). 
Initially, the array 
2-3
JH-C couplings in CD3OD for fragment C appeared 
perplexing and structurally uninformative; however, by expanding our assessment of 
this portion of 3.9 to include additional HMBC coupling detected in CDCl3, we were 




C correlations that were useful for revealing the 
composition of this substructure. The first set consisted of correlations from a doublet 
proton at δH 4.12 (J = 3.7 Hz, 1H) to carbons at δC 22.8, 22.9, 52.9, and 178.1. Upon 
considering the chemical shifts of these carbons and their respective numbers of 
attached protons (determined by 
1
JH-C HSQC), we were able to deduce that they 
represented two aliphatic methyl groups, a methylene, and a quaternary carbon, 




H COSY correlation from the proton at δH 4.12 
to geminal protons attached to the carbon δC 22.9 [based on 
1
JH-C HSQC; δH 1.88 (m, 
1H) and 2.17 (m, 1H)]. These protons in turn coupled with a second set of geminal 
protons (δH 1.48, m, 1H and δH 2.04, m, 1H) that were attached to a carbon at δC 33.5 
(based on 
1
JH-C HSQC). Additional 
2-3
JH-C couplings were found that originated from a 
methyl singlet at δH 1.03 and extended out to carbons at δC 28.3, 38.4, 52.9, and 86.1, as 
well as from a proton triplet at δH 1.50 (J = 3.4 Hz, 1H) to carbon resonances at δC 23.2, 
28.3, 38.4, and 178.1. The abundance of carbons shared among at least two of the three 
sets of 
2-3
JH-C couplings enabled us to construct a cyclohexane substructure with an ester 




fragment C). Further consideration of the downfield shift observed for the carbon at δC 
86.1 and the 
3
JH-C coupling exhibited by its attached proton to the ester carbonyl 
resonance (δC 178.1) led us to deduce the presence of a second fused ring in fragment C.  
Thus, fragment C was proposed to consist of a 7,7-dimethyl-2-oxabicyclo[2.2.2]octan-
3-one system (Figure 3.2A). 
With the establishment of fragments A-C, only a handful of atoms remained to 
be assigned (C4H7O2). Three of the remaining protons belonged to a methyl singlet (δH 
3.58, 3H) that was judged by its chemical shift and 
3
JH-C HMBC coupling to be 
associated with an ester carbonyl (δC 172.7). Since no other correlations were observed 
from the other fragments to any of the atoms in fragment D (Figure 3.2A), we waited to 
assign its position in the metabolite until other evidence was secured. Fragment E 





COSY data showing the coupling of their attached protons (geminal protons at δH 1.60 
and 1.37 coupled to a second set of geminal protons at δH 2.10 and 2.08). 
With all of the atoms accounted for in 3.9, the final task was to determine the 
linkages among fragments A-E.  Reexamination of the 
2-3
JH-C HMBC data showed that 
the methyl protons at δH 1.22 in fragment B exhibited a 
3
JH-C coupling with the ketone 
resonance (δC 201.8) in fragment A. With no other 
2-3
JH-C couplings apparent, we 
considered the fact that one of the quaternary carbons in fragment B (δC 69.8) was still 
lacking two of its four required bonding groups. We deduced that the enol carbon (δC 
192.1) in fragment A was joined to this quaternary carbon in fragment B, which resulted 
in a five-membered 3-hydroxy-2-methylcyclopent-2-enone system. A series of three 
additional 
2-3




and E (fragment B δH 1.36 → fragment E δC 32.9, fragment B δH 5.44 → fragment C δC 
46.7, and fragment C δH 1.50 → fragment E δC 23.2) and this enabled us to establish the 
final ring system required for 3.9. With only two unbonded carbon atoms left, we 
concluded that the ester comprising fragment D must be attached to the remaining 
quaternary carbon (δC 69.8) in fragment B. 
With the planar structure of 3.9a established, the assignment of the relative 




H ROESY experiment. We observed a set of reciprocal correlations among several 
of the cyclohexene’s substituents including H-22 ↔ H-11 and H-23, H-23 ↔ H-26 and 
H-21, and H-26 ↔ H-21 (Figure 3.2B). These data supported a cis fusion between the 
five-membered 3-hydroxy-2-methylcyclopent-2-enone and the cyclohexene ring 




H ROESY correlations among three of 
the four axial protons of the cycloalkane (H-7axial ↔ H-9axial ↔ H-5axial) (Figure 3.2B).  
This enabled us to establish the relative configuration of 3.9a as 3R*, 5R*, 8S*, 9R*, 
10S*, 13R*, 14R*. During the process of characterizing the structure of 3.9a, we were 
able to secure a crystal of the metabolite from methanol that was suitable for X-ray 
crystallography. An ORTEP drawing of 3.9a derived from the X-ray diffraction 
analysis is illustrated in Figure 3.4. In addition to verifying the proposed relative atom 
configuration for 3.9a, we were also able to confirm the compound’s absolute 
configuration as 3R, 5R, 8S, 9R, 10S, 13R, 14R. Considering the unique Atlantic Forest 





 Figure 3.4.  ORTEP structure for 3.9a 
generated from the X-ray diffraction 
data. 
At this point in the investigation, we returned our attention to the occurrence and 
population distribution of the three potential tautomers of 3.9 (Figure 3.3). Whereas the 
keto-enol tautomer 3.9a (Figure 3.3) was readily apparent in methanol (C-17 ketone and 
C-15 enol carbon), we were not able to detect any traces of the complementary keto-
enol tautomer (C-15 ketone and C-17 enol carbon) in solution. We suspect this may be 
due to the stabilizing influence of intramolecular hydrogen bonding between the C-15 
enol hydroxyl group and the C-25 carbonyl oxygen atom. However, it is interesting to 




 which share similar cis-fused 
cyclohexene and 3-hydroxy-2-methylcyclopent-2-enone substructures with 3.9, are 
reported to exhibit a preference in methanol or chloroform for a single tautomeric 
species. Instead both sets of compounds undergo rapid transitions between their keto-
enol and β-diketone forms in solution. We also noted that the corresponding β-diketone 




H ROESY data for 3.9b in CDCl3 showed that both 16R and 16S configurations were 





A related metabolite (3.10) was detected in one of the HPLC fractions that 
eluted just after 3.9.  HRESIMS showed that 3.10 varied from the latter by the addition 
of an oxygen atom (m/z 481.2203 [M + Na]
+
 consistent with a molecular formula of 




C NMR data for 3.10 
collected in CDCl3 (Table 3.1) showed remarkable similarity to 3.9b with one exception: 
C-16 was shifted substantially downfield (δC 72.5 in 3.10 versus δC 51.4 in 3.9b) and its 
attached proton was missing (based on 
1
JH-C HSQC). This suggested that 3.10 was the 
C-16 hydroxy analog of 3.9b and it was given the name atlantinone B. The remaining 
structural similarity between 3.10 and 3.9b was quickly confirmed via analysis of the 
new metabolite’s 
2-3





spectrum for 3.10 revealed a correlation between the H-24 methyl protons and the H-26 
methyl ester, which suggested an R configuration for C-16. In light of the these data and 
considering that compounds 3.9 and 3.10 have a shared biogenic origin, we propose that 
the absolute configuration of 3.10 is 3R,5R,8S,9R,10S,13R,14R,16R. 
A substantial portion of the atlantinones’ structures are similar to other fungal-
derived meroterpenoids such as citreohybriddiones A and B.
72
 This group of 
compounds is proposed to arise from the C-alkylation of 3,5-dimethylorsellinate with 
farnesyl pyrophosphate, which is subjected to cyclization and further functionalization, 
yielding a diverse assemblage of products.
73
 Geris and Simpson
73
 recently hypothesized 
that the biosynthetic machinery responsible for generating a wide range of homologous 
meroterpenoids from Aspergillus and Penicillium (e.g., andrastins, berkeleyones, 
penisimplicin, and territonin) is likely achieved by means of structural elaboration upon 




dimethyl-2-oxabicyclo[2.2.2]octan-3-one bridged-bicyclic-ring system, constitute a new 
branch of unusual structural diversification within this metabolite family. 
The preponderance of secondary metabolites in the guttate of epigenetically 
modified P. citreonigrum (Figure 3.1C and 1D) suggests that fungal exudates warrant 
further exploration as a resource for natural product exploration. Considering the 
proposed role that guttates might play as nutrient sources for symbiotic microbial 
species, we rationalized that fungal hosts could incorporate bioactive compounds into 
exudates to influence the composition of the developing microbial community’s 
structure. Accordingly, we tested 3.1-7, 3.9, and 3.10 against a panel of bacteria and 
fungi to ascertain if these compounds exhibited antimicrobial activities.  Out of the nine 
compounds, only 3.1 and 3.6 exhibited modest zones of inhibition in a disk diffusion 
assay at a concentration of 30 µg/6mm paper disk.  Both 3.1 and 3.6 inhibited 
Staphylococcus epidermidis (both produced 8 mm zones of inhibition), whereas only 
3.6 inhibited Candida albicans, Candida parapsilosis, Candida tropicalis, and Candida 
krusei (8, 7, 8, and 8 mm zones of inhibition, respectively).  In contrast, gentamicin (15 
µg/6mm paper disk) exhibited more substantial zones of inhibition that averaged 8-16 
mm against a range of bacteria, while ketoconazole (15 µg/6 mm paper disks) produced 
zones of inhibition that averaged 15-26 mm against a panel of yeast.  The modest 
antimicrobial activities of the azaphilones were not surprising given the similar results 
that have been reported for other members of this secondary metabolite family.
74
  
However, we did find that our data stood in disagreement with results that had been 
recently reported for 3.7.  Whereas Lucas and colleagues observed modest activity for 




Escherichia coli, and Candida albicans (13-16 mm zones of inhibition using 100 
µg/disk),
69b
 we observed no activity for this metabolite against 10 Gram-negative and 
Gram-positive bacteria and five fungi at concentrations ranging up to 135 µg/disk.  
Further studies of the secondary metabolites found in fungal guttates are required to 










Table 3.1.  
1
H (500 MHz) and 
13
C (125 MHz) NMR data for 3.9a (CD3OD), 3.9b (CDCl3), and 3.10 (CDCl3) 
atlantinone A (3.9a)  atlantinone A (3.9b)  atlantinone B (3.10) 
Position δC δH, mult (J in Hz) HMBC  δC δH, mult (J in Hz) HMBC  δC, δH, mult (J in Hz) HMBC 
1 33.5 1.48 (1H, m) 3, 5, 10 32.6 1.39 (1H, m) 18  32.6 1.43 (1H, m) 3, 10 
  2.04 (1H, m) 6   2.05 (1H, m)    2.09 (1H, m)  
2 22.9 2.17 (1H, m) 5, 18  21.8 2.07 (1H, m) 5  21.8 2.13 (1H, m) 1 
  1.88 (1H, m) 3   1.89 (1H, m) 3   1.95 (1H, m) 3 
3 86.1 4.12 (1H, d, 3.7) 2, 5, 18 84.4 4.07 (1H, d, 3.6) 1, 5, 18, 19 84.4 4.11 (1H, d, 4.0) 1, 2, 5, 18 
4 38.4    37.4    37.4   
5 52.9 1.50 (1H, t, 3.7) 6, 18, 20 51.3 1.44 (1H, m) 4, 20  51.2 1.49 (1H, m) 1, 4, 18 
6 23.2 1.60 (1H, m) 5  21.9 1.56 (1H, m) 8, 10  21.8 1.50 (1H, m)  
  1.37 (1H, m) 5   1.42 (1H, m) 5, 10   1.60 (1H, m)  
7 32.9 2.10 (1H, m) 5, 9  30.1 2.39 (1H, m) 8  30.0 2.58 (1H, td, 4.5, 13.0) 5, 8, 9 
  2.08 (1H, m) 5, 9   2.28 (1H, dt, 13.7, 3.5) 5   2.25 (1H, m) 14 
8 43.0    39.7    38.8   
9 47.6 1.90 (1H, m) 18, 21  47.2 1.82 (1H, m) 11, 12 46.6 1.96 (1H, t, 3.0) 8, 11, 18 
10 46.7    45.0    45.0   
11 126.3 5.44 (1H, s) 8, 10, 13, 22 127.4 5.67 (1H, s) 9, 10, 13, 22 129.4 5.82 (1H, s) 8, 9, 13, 22 
12 134.7    132.0    131.0   
13 57.5    61.1    61.3   
14 69.8    73.3    71.7   
15 192.1    211.3    211.5   
16 113.7    51.4 3.20 (1H, q, 6.7) 15, 17, 24 72.5   
17 201.8    209.6    207.5   
18 178.1    174.8    174.9   
19 22.8 1.03 (3H, s) 4, 20  22.6 1.02 (3H, s) 3, 4, 5, 20 22.6 1.06 (3H, s) 3, 4, 5, 20 
20 28.3 1.14 (3H, s) 4, 19  28.1 1.07 (3H, s) 3, 4, 5, 19 28.0 1.12 (3H, s) 3, 4, 5, 19 
21 17.6 1.36 (3H, s) 7, 8, 9, 14 16.5 1.32 (3H, s) 7, 8, 10 16.9 1.35 (3H, s) 7, 8, 9, 14 
22 20.3 1.82 (3H, s) 11, 12, 13 19.2 1.69 (3H, s) 11, 12, 13, 14 19.1 1.76 (3H, s) 11, 13 
23 16.7 1.22 (3H, s) 12, 13, 14, 17 16.5 1.32 (3H, s) 12, 13, 14, 17 17.7 1.41 (3H, s)  12, 13, 14, 17 
24 6.7 1.57 (3H, s) 15, 16, 17 9.6 1.19 (3H, d, 6.8) 15, 16, 17 19.9 1.38 (3H, s) 15, 16, 17 
25 172.7    168.3    167.6   
26 52.0 3.58 (3H, s) 25  52.0 3.54 (3H, s) 25  52.1 3.61 (3H, s) 25 
OH               
  







3.3 Materials and Methods 
3.3.1 General Methods 
NMR data were obtained on Varian VNMR spectrometers (400 and 500 MHz 
for 
1
H, 100 and 125 MHz for 
13
C) with broad band and triple resonance probes at 20 ± 
0.5 
°
C.  Electrospray-ionization mass spectrometry data was performed on a LCT 
Premier (Waters Corp.) time-of-flight instrument.  Optical rotations were measured on a 
Rudolph Research Autopol III automatic polarimeter. HPLC separations were 
performed on a Shimadzu system using a SCL-10A VP system controller and Gemini 
5µm C18 column, (110Å, 250 x 21.2 mm) with flow rates of 1 to 10 mL/min.  X-ray 
diffraction data were collected on a Bruker-AXS with an APEX CCD area detector with 
a Cu X-ray source.  All solvents were of ACS grade or better. 
3.3.2 Organism Collection, Identification, and Culture Methods 
A soil sample (~100 g taken from about 20 cm below the soil surface) was 
collected in a small patch of remnant forest near the coast of Joao Pessoa, State of 
Paraíba, Brazil in January of 2006.  Samples (1 g) were placed in autoclaved H2O (10 
mL) and diluted 10- and 100-fold.  Aliquots (300 uL) of the diluted soil suspensions 
were lawned onto the surfaces of 10 cm diameter Petri plates containing potato-dextrose 
agar with chloramphenicol (100 mg/L) and cycloheximide (100 mg/L).  Plates were 
maintained at 20 °C for four weeks and emerging colonies were picked from the plates 
and transferred to fresh Petri plates containing potato-dextrose agar with 
chloramphenicol (100 mg/L).  This process was repeated for each isolate until a uniform 
fungal colony was established.  Fungi were transferred to new Petri plates containing 
potato-dextrose agar and after 2-3 weeks of incubation at 20 °C, pieces of the agar 
containing mycelia (~0.5 cm
2




sterile glycerol-H2O (15:85).  The tubes were then stored at -80 °C until the fungus was 
needed for scale-up studies.  The fungus was identified based on sequence analysis of a 
321 base-pair portion of its large ribosomal subunit 28S rRNA gene using a previously 
published method.
53b
  The sequence of the isolate was compared by BLAST analysis to 
sequences publically available through the NCBI database. 
For the preparative-scale grow-up, fungal mycelia and spores were inoculated 
into 50 mL potato-dextrose media and grown for one week with shaking (125 rpm).  
The cellular material was placed in a sterile Falcon tube and mixed by vortexing for 
several minutes to create a uniform fungal cell/spore suspension.  Aliquots (500 µL) of 
the fungal suspension were used to inoculate 110 Erlenmeyer flasks (1 L) containing 
autoclaved media (0.1 g rice, 0.1 g oatmeal, 0.1 g cornmeal, 0.32 g nutrient broth, ~0.5 
g vermiculite, and 50 mL of deionized H2O).  Epigenetically modified cultures were 
treated with 50 µM 5-azacytidine, while the control cultures were treated with vehicle 
only (filter-sterilized H2O).  Culture vessels were maintained on the bench-top at 25 °C 
for 20 days. 
3.3.3 Extraction and Isolation 
The guttate-covered mycelia mats were washed by adding 100 mL of EtOAc to 
each flask and gently swirling the contents.  The liquid was decanted from the flasks, 
pooled, and placed in a separatory funnel.  The organic layer was recovered and the 
solvent was removed under vacuum.  The resulting organic extract was resolubilized in 
MeOH and partitioned three times against an equal volume of hexane.  Solvent from the 
defatted MeOH extract was removed under vacuum, which yielded a rust-colored crude 
extract (0.8 g).  The extract was subjected to gradient C18 HPLC (mobile phase 20% to 




fraction A (40 mg of 7), fraction B (160 mg mixture of 3.9 and 3.10), and fraction C 
(182 mg mixture of azaphilones 3.1-3.6).  Fraction B was subjected to repeated semi-
preparative C18 HPLC (mobile phase 75% to 100% MeOH in H2O), which provided 3.9 
(7 mg) and 3.10 (3 mg).  The azaphilones in fraction C were purified in two additional 
steps.  The first step consisted of passing the mixture over silica gel in a step gradient 
fashion with hexane and increasing amounts (10% increments) of acetone.  The second 
step involved applying a portion of the fractions containing the azaphilones to semi-
preparative C18 HPLC (mobile phase 80% to 100% MeOH in H2O) to give purified 3.1-
3.6. 
3.3.4 Sclerotioramine (3.6) 
Red solid;
 1
H NMR (400 MHz, CDCl3) δH 7.80 (1H, s, H-1), 6.79 (1H ,s ,H-4), 
6.10 (1H, d, J = 16.0 Hz, H-9), 6.95 (1H, d, J = 16.0 Hz, H-10), 5.68 (1H, d, J = 9.8 Hz, 
H-12), 2.47 (1H, m, H-13), 1.44 (1H, m, H-14), 1.34 (1H, m, H-14), 0.88 (3H, t, J = 7.4 
Hz, H-15), 1.04 (3H, d, J = 6.7 Hz, H-16), 1.85 (3H, s, H-17), 1.58 (3H, s, H-18), 2.23 
(3H, s, H-20); 
13
C NMR (100 MHz, CDCl3) δC 138.4 (CH, C-1), 146.1 (C, C-3), 110.5 
(CH, C-4) , 146.6 (C, C-4a), 102.1 (C, C-5), 183.1 (C, C-6), 85.6 (C, C-7), 193.4 (C, C-
8), 114.2 (C, C-8a), 116.3 (CH, C-9), 143.0 (CH, C-10), 132.1 (C, C-11), 149.1 (CH, C-
12), 35.3 (CH, C-13), 30.2 (CH2, 14), 12.2 (CH3, C-15), 20.3 (CH3,C-16), 12.6 (CH3, C-
17), 23.7 (CH3, C-18), 171.4 (C, C-19), 20.8 (CH3, C-20); HRESIMS m/z: [M+Na]
+
 
412.1290 (calcd for C21H24NO4ClNa, 412.1292). 
3.3.5 Pencolide (3.7) 
White solid; 
1
H NMR(500 MHz, CDCl3), δH 7.40 (1H, q, J = 7.0 Hz, H-3), 1.81 
(3H, d, J = 7.0 Hz, H-4), 6.46 (1H, q, J = 2.0 Hz, H-4'), 2.13 (3H, d, J = 2.0 Hz, H-6'); 
13




(CH3, C-4), 170.2 (C, C-2'), 146.7 (C, C-3'), 128.3 (CH, C-4'), 169.1 (C, C-5'), 11.7 
(CH3, C-6'); HRESIMS m/z: [M+Na]
+
 218.0432 (calcd for C9H9NO4Na, 218.0429). 
3.3.6 Preparation of Pencolide Methyl Ester (3.8) 
Thionyl chloride (0.10 mmol) was slowly added to a solution of dry MeOH (1 
mL) and pencolide (7, 0.051 mmol) under a N2 atmosphere at 0
o
 C.  The mixture was 
allowed to slowly warm to room temperature with stirring.  After 12 hours, the excess 
MeOH was removed under high vacuum and the crude material was subjected to 
partitioning with EtOAc and H2O.  The organic layer was collected, dried by passing 
over magnesium sulfate, filtered, and the solvent was removed under vacuum.  The 
sample was then subjected to HPLC (C18, 5% to 15% MeOH in H2O) providing 
pencolide methyl ester (8) in 58% yield (6.2 mg, 0.030 mmol).  
1
H NMR (400 MHZ, 
CDCl3), δH 7.30 (1H, q, J = 7.2 Hz, H-3), 1.77 (3H, d, J = 7.2 Hz, H-4), 6.44 (1H, q, J = 
2.0 Hz, H-4'), 2.13 (3H, d, J = 2.0 Hz, H-6'), 3.73 (3H, s, COOCH3); 
13
C NMR (100 
MHZ, CDCl3), δC 163.3 (C-1), 123.3 (C-2), 143.5 (C-3), 14.5 (C-4), 170.3 (C-2'), 146.7 
(C-3'), 128.3 (C-4'), 170.3 (C-5'), 11.5 (C-6'), 52.8 (COOCH3) 
3.3.7 Atlantinone A (3.9) 
Colorless, crystalline solid; [α]
21





data, see Table 3.1; m/z 465.2256 [M + Na]
+
 (calcd for C26H34O6Na, 465.2253). 
3.3.8 X-ray Crystallographic Analysis of Atlantinone A (3.9)  
C26H34O6  CH4O, FW = 474.57, orthorhombic, P212121, a = 12.0199(6), b = 
13.7713(6), c = 14.8276(8) Å, Volume = 2454.4Å
3
, Z = 4, calc = 1.284 Mg/m
3
, Cu K 
radiation,  = 1.54178 Å.  Intensity data were collected on a Bruker instrument with an 




100 K.  A total of 26,979 data points were collected using ω and  oscillation frames to 
give 4,555 unique data out to 67  with a Rint = 0.0476 and 100.0% coverage.  All data 
were included in the refinement of F
2
 values.  Hydrogens bonded to carbons were 
included with assumed geometries and refined with a riding model.  Hydrogens bonded 
to oxygens were located on a difference map, and their positions were refined 
independently.  Final wR2 = 0.0802, R1 = 0.327, S = 1.001. 
3.3.9 Atlantinone B (3.10) 





C NMR data, see Table 3.1; m/z 481.2203 [M + Na]
+
 (calcd 
for C26H34O7Na, 481.2202). 
3.3.10 Analysis of Guttate Metabolites 
Cultures treated with 50 µM 5-azacytidine and vehicle controls were prepared in 
triplicate using the method described for the scale-up metabolite isolation studies (vide 
supra).  The cultures were incubated for 20 days and the guttates were sampled by 
pinching them off at their bases from the mycelia surface using a pair of fine-tip forceps.  
We initially experimented with employing a syringe to aspirate the guttate, but were not 
able to use this approach since both the control and treatment group guttates were quite 
resinous in consistency.  Instead, a total of 25 equal-sized guttate droplets were freed 
from the mycelia in control and treated cultures and were placed in separate Eppendorf 
tubes.  Control and treated guttates were washed three times with 500 µL of MeOH and 
the organic extracts were centrifuged to remove solids.  The MeOH soluble materials 
were passed over a C18 SPE cartridge and subjected to C18 HPLC (mobile phase 20% to 




purified 3.1-3.7 and 3.9 and 3.10 were used to authenticate components in the treated 
and control samples. 
3.3.11 Antimicrobial Assay 
Compounds were tested for antimicrobial activity using a disk-diffusion assay.  
Seed cultures of eight bacteria (Staphylococcus aureus ATCC 700787, Staphylococcus 
epidermidis ATCC 12228, Burkholderia cepacia ATCC 25608, Klebsiella pneumoniae 
ATCC 33495, Actinobacter baumannii ATCC 19606, Pseudomonas aeruginosa ATCC 
10145, Escherichia coli ATCC 11775, and Enterobacter cloacae ATCC 13047,) and 
five fungi (Candida albicans ATCC 12983, Candida parapsilosis ATCC 12969, 
Candida glabrata NRRL Y-65, Candida tropicalis ATCC 12968, and Candida krusei 
ATCC 27803) were prepared by incubating the organisms for 10 h at 30 °C (fungi) or 
37 °C (bacteria).  Aliquots of the overnight cultures (80 µL) were lawned onto the 
surfaces of nutrient agar (bacteria) or yeast extract agar with 2% (w/v) glucose (fungi).  
Sterile filter disks (6 mm diameter) infused with 3 µL of test solution (10 µg/µL 
DMSO), positive control (5 µg/µL DMSO gentamicin for bacteria or 5 µg/µL DMSO 
ketoconazole for fungi), or vehicle only (DMSO) were added to the plates.  The plates 
were left upright for 30 minutes at room temperature before being placed in an 
incubator at 30 °C (fungi) or 37 °C (bacteria).  After 10 h, the diameters of the zones of 





Chapter 4 Novel dimeric isoprenylated  indole alkaloids  isolated  from 
Aspergillus sp. by manipulating the culture conditions 
This chapter is adapted from publication that is currently under preparation. 
4.1 Introduction 
During our continuing study of new fungal metabolites a fungus Aspergillus sp. 
from Hawaii was investigated. In our group we have continually applied the chemical 
epigenetic method for producing secondary metabolites from fungi.
51
  This method has 
been demonstrated as an effective tool for promoting the transcription of silent 
biosynthetic pathways involved in the formation of polyketide, non-ribosomal peptide, 
and hybrid polyketide-non-ribosomal-peptide natural products. 
75
 In this study, we have 
applied different epigenetic modifiers on this fungus and compared its secondary 
metabolites production by LC-MS respectively. In the meantime, we also compared the 
secondary metabolite production by growing this fungus in the liquid and static medium. 
4.2 Results and Discussion 
LC-MS has been used to analyze the secondary metabolite production in each 
culture condition. Fungi treated with suberoylanilide hydroxamic acid (SAHA) or 5-
Azacytidine (5-Aza) showed increasing yield of secondary metabolite which 
demonstrated epigenetic modification can upregulate the fungal secondary metabolites 
gene expression. Based on LC-MS guided separation we have focused on those 
compounds with a mass higher than 400 amu under the static condition. A series of 
compounds had been isolated and quickly dereplicated based on their 
1
H NMR and 













,  stephacidin A (4.5)
79
 and CJ-17665 (4.6) 
80
. 
Compound 4.7, a yellow plate (MeOH), HRESIMS analysis provided a 
pseudomolecular ion with a m/z of 875.4119 [M+H]
¯
 that was consistent with a 
molecular formula of C52H54N6O7 (calcd for C52H55N6O7, 875.4132),  indicating 29 
degrees of unsaturation. 
1
H-NMR suggested that this compound maybe a mixture of 
two alkaloids. However, the single peak in the HPLC profile and the HRESIMS data 
confirmed this was only one compound belonging to a class of prenylated indole 
alkaloids.
 
 Analysis of HSQC and 
1
H-NMR (table 4.1) revealed 8 singlet methyl signals 
at δH 1.02 (s, 3 H), 1.15 (s, 3 H), 1.26 (s, 3 H), 1.28 (s, 3 H), 1.37 (s, 3 H), 1.39 (s, 3 H), 
1.68 (s, 3 H), and 1.83 (s, 3 H), 10 methylene signals in a range of δH 1.8 -2.8, 8 doublet 
olefinic signals at δH 5.52 (d, J = 10.5 Hz), 7.56 (d, J = 10.5 Hz), 6.44 (d, J = 8.3 Hz), 
6.89 (d, J = 8.3 Hz), 6.64 (d, J = 8.3 Hz), 7.14 (d, J = 8.8 Hz), 5.58 (d, J = 9.8 Hz), and 
6.40 (d, J = 9.3 Hz). 4 methine at δH 5.55 (s), 5.14 (s,) 3.08 (dd, J = 10.3, 6.7 Hz), and 
3.00 (m, 1H), and two exchangeable protons at δ 7.58 (s, 1 H) and 7.44 (s, 1 H).  
13
C 
NMR signals at δC 174.3, 174.2, 168.8, and 167.1 implied the presence of four carbonyl 




C NMR spectra of 
compound 4.7 are similar to those of stephacidin B which is a dimer of CJ-17665 
(avrainvillamide)
81
. The molecular weight difference of m/z 16 between 4.7 and 
stephacidin B indicated the absence of one less oxygen atom in 4.7. Extensive 2D-NMR 
studies including COSY, HMBC and NOESY have been used to establish all structural 















chemical shifts of C-1 and C-4 indicated a 5-membered ring having nitrogen between 
them. The methylene protons H-5 and H-6, vicinally connected with H-5, were coupled 
to the C-4 and the amide carbonyl group (C-23); the 5-H and 3-Ha showed long range 
couplings to the remaining amide carbonyl group at C-26, which resulted in the 
formation of amide bridge between C-22 and C-4 to produce diketopiperazine 
substructure. Two singlet methyl protons H-27 and H-28 were coupled to C-7 and C-8 
and H-6 was coupled to C-5, C-7. Furthermore, a singlet methine proton at H-21 was 
coupled to C-20, C-22 and C-23.Those described correlations enabled us to propose the 
partial structure A (Fig. 4.1A) Similarly, the partial structure B was determined based 













H-) which have HMBC correlations from 
H-12 to C-10, C-14 and C-16, from H-13 to C-11, C-14; from H-17 to C-11, C-16 and 
an C-19, from H-18 to C-10,C-11 and C-16. Two singlet non-equivalent methyl groups 
were, in addition, coupled to C-13 and C-14. The position of O-15 was deduced by the 
oxygenated features of chemical shifts C-14 and C-16. All above correlations enable us 
to establish the partial structure (B). Based on the chemical shifts of C-8 (δC 151.3) and 
C-10 (δC 140.0) we postulated that nitrogen was present between C-8 and C-10, 
furthermore, a key HMBC correlation from H-21 to C-19 was observed. Finally, partial 
structure A and B was linked from C-10 to N-9 and from C-19 to C-20 to give 
substructure which was identified as CJ17665 (4.6). HMBC correlations from an 
exchangeable proton at δH 7.58 to C-38 and 50 connected fragment A1 and B1 to give 
the planar structure that was identified as stephacidin A (4.5). The HMBC correlations 




51 and a correlation from H-21 to C-52 confirmed the linkage between C-21 and N-55. 
Thus heterodimer (4.7) is originated from CJ-17665 (4.6) and stephacidin A (4.5). We 
named it as waikialoid A. A crystal grew from 100% MeOH under room temperature 
was obtained and its structure was confirmed by single-crystal X-ray analysis (Figure 
4.4). X-ray analysis provided the absolute configuration of 4.7 as 4S,6S,20S,21S,22R, 
34S,36S,51R,52R.   
 
 
Figure 4.1.  Correlations obtained from 
2-3




H COSY experiment that were used to 
generate fragments A-B which were critical for deducing the structure of 4.7 (A)  Key 
2-3
JH-C HMBC 











HRESIMS analysis of compound 4.8 provided a pseudomolecular ion with a m/z 
of 905.3827 [M-H]
 ̄
that was consistent with a molecular formula of C52H54N6O9 (calcd 
for C52H53N6O9, 905.3874), indicating 29 degrees of unsaturation. Based on the HMBC 
and HSQC we were able to assign chemical shifts to all carbon atoms although we did 
not obtain a well resolved carbon signal. By carefully analyzing the NMR data (table 
4.1), compound 4.8 showed a similar 
1
H NMR spectrum as that of compound 4.7 (table 
4.1) indicating a third natural occurring dimer of prenylated indole alkaloid type 
compound. The molecular weight difference of m/z 32 between 4.8 and 4.7 indicated 
the presence of two more oxygen atoms in 4.8.  The IR spectrum showed a 
distinguished absorption band at 3380 indicating an OH group in 4.8. The HMBC 
correlations from OH-62 to C-49, 50 and 51 were used to confirm the position of OH 
group at C-50. By carefully analyzing the HMBC and HSQC data we did not see any 
significant chemical shift changes, so two other oxygen atoms must attach to the N-9 
and N-39. Thus compound 4.8 is a heterodimeric metabolite derived from CJ-17665 and 
aspergamide A 
162
. The linkages between these two compounds were identified at the 
same way as that of 4.7 by HMBC correlations from H-51 to C-8 and C-20, and H-21 to 




H ROESY experiment. We observed a set of reciprocal correlations including H-51 ↔ 
H-48, OH-62, H-6, H-28, H-36 ↔ H-17, H-35b and H-58, H-21↔ H-25, H-17, H51, H-
6, OH-62 ↔H27, H51 and H-57. This enabled us to establish the relative configuration 
of 4.8 as 4S*,6S*,20S*,21S*,22R*,34S*,36S*,50R*,51R*,52R*. The CD spectra of 




which indicated that they had the same absolute configuration. So we determined the 
absolute configuration of compound 4.8 as 4S,6S,20S,21S,22R,34S,36S,50R,51R,52R.  
Besides compounds 4.1-8, six other known compounds were isolated and 
identified as circumdatin  F (4.9) 
82
, circumdatin C (4.10) 
83








from the static culture.  
 Liquid culture provides less secondary metabolites and we did not observe any 
of the above compounds except circumdatin F and circumdatin C from this fungus. 
Compound 4.15 and 4.16 are exclusively isolated from liquid culture.  
Compound 4.15 has a molecular formula C14H20O2Na based on HRESIMS m/z 
243.1378 (Calcd: 243.1360), indicating 5 degrees of unsaturation. Based on the HSQC 
and 
1
H-NMR there are 2 singlet methyl signals at δH 0.93, 1.78, 6 olefinic signals at δH 
5.73, 6.13 (×4), and 5.55, 3 methine at δH 1.95, 2.25, 3.78 (oxygenated), and a series of 
overlapping multiplets spanning the region δH 1.6-2.7. By analysis of the 
13
C NMR it 
showed there were 6 olefinic carbons at δC 130.5, 133.2, 133.6, 131.7, 133.0, 136.4 and 









was revealed by the 
2-3
JH-C HMBC correlations from H-10 
to C-8 and C-9 , in addition, the 
2-3
JH-C HMBC correlations from H-11b to C-9, C-10, 










-. Thus the partial 
structure A was proposed as cyclohexanone ring moiety (Figure 4.2). The COSY 
correlations between a methyl group δH 1.78 and an olefinic proton δH 5.73 connected 
C-1 with C-2. HMBC correlations from overlapped δH 6.13 to δC 130.5, 131.7 and 133.0 




incorporation of the assignments together compound 4.15 was determined as 3-((1E, 3E, 
5E)-hepta-1, 3, 5-trien-1-yl)-5-hydroxy-2-methylcyclohexanone. The relative 
configuration was determined using J-based coupling constant analysis and NOESY 
experiments.  The sp3 methine proton H-8 showed NOE correlations with H-10 and H-
13; In addition, the large coupling constant ( J13, 8 = 13.0 Hz) indicated that they should 
be axial and axial oriented. The H-10 showed axial-axial coupling to H-9a (d, J = 
11.3Hz) and H-11a (d, J = 11.4Hz).  These couplings enabled us to deduce its relative 
configuration as 8S*, 10R*, and 13R*. Considering the origin of compound 4.15 from 
the Aspergillus sp. with hydroxyl group in the structure we have given 4.15 the name 
asperonol A. A crystal grew from 100% MeOH under room temperature was obtained 
and its structure was confirmed by single-crystal X-ray analysis (Figure A1).  
 
     
                                     
 Figure 4.2. (A)  Correlations obtained from 2-
3
JH-C HMBC experiment that were used to 
generate fragments A-B, which were critical for 





NOESY correlations that were used to help 






The absolute configuration of the tertiary alcohol at C-10 was determined by the 
Mosher ester method
87
. Comparing the 
1
H NMR showed a slight difference of δH 
caused by the diamagnetic effect of the α-methoxy-α-(trifluoromethyl)phenylacetic acid 
(MTPA) benzene ring ( Figure 4.3). The absolute configuration of C-10 was determined 
as 10R as calculation of the ∆δSR = δH(S) - δH(R). We also used CD spectrum to confirm 
the absolute configuration. Compound 4.15 showed a negative Cotton effect resulting 
from n-π* transition at 290 nm indicative of a 13R configuration based on the octant 
rule.
15
 The absolute configuration from CD was agreed with the assignment from 
Mosher ester method. So the absolute configuration was determined as (8S,10R,13R) - 
3-((1E, 3E, 5E)-hepta-1, 3, 5-trien-1-yl)-5-hydroxy-2-methylcyclohexanone.  
Figure 4.3. Values of δS-δR of the MTPA esters 
of 4.15 
Compound 4.16 has a molecular formula C14H22O2 based on HRESIMS 
221.1543 [M-H]
¯
 (Calcd: 221.1542) indicating 4 degree unsaturation. The 
1
H NMR 
showed compound 4.16 is structurally close to compound 4.15. Carbon NMR revealed a 
new carbon at δC 72.8 accompanying with a loss of a carbonyl group compared to those 
of compound 4.15. This change also made H-11 and H-13 shift more upfield in 
compound 4.16. All evidences supported that the structural change at C-12 from a 
carbonyl to an oxygenated methine. Based on the HMBC and COSY correlations 
compound 4.16 is a C-12 hydroxyl analog of 4.15 and it was named asperonol B. The 




reciprocal correlation including H-8 ↔ H-11a, H-6, H-12 ↔ H-8, H-13, H14, H-13 ↔ 
H-7, H-12 and H-14, H-10 ↔ H- 9b which helped us to determine the relative 
configuration as 8S*, 10R*, 12R* and 13R*. Because compound 4.16 and 4.15 had 
close planar structure and positive specific rotation we proposed the absolute 
configuration of compound 4.16 as 8S, 10R, 12R and 13R.  
The effects of compounds 4.1-10, 4.13-16 on C. albicans growth and biofilm 
formation were evaluated in 96-well polystyrene microplates. C. albicans cells were 
treated with various concentrations (6.25–200 µM) of test compounds or DMSO as 
negative control at 37 ºC for 48 h. The growth and biofilm formation of C. albicans 
were measured using XTT assay. The samples were compared to the negative controls 
to determine any reduction in the total amount of growth or biofilm. Test compounds 
did not inhibit the growth of C. albicans at 200 µM while eight of them showed the 
biofilm inhibition activity (Table 4.3). In the bioassays of the isolated metabolites, 
compound 4.1, 4.2, 4.4, and 4.16 showed low activity (IC50 >80 μM). Compound 4.5, 
4.6 and 4.8 exhibited a similar moderate activity, while 4.7 and 4.15 were the most 
potent compounds, with IC50 of 32.36 μM and 1.40 μM, respectively. And the effects of 
compounds 4.7 and 4.15 on C. albicans hyphae formation were observed under a phase 
contrast microscope. 7 and 15 inhibited the hyphae formation in a dose dependent 
manner.  C. albicans cells treated with DMSO formed germ tubes at 2.5 h, hyphae at 6 
h, biofilms at 24 h, while the cells treated with 4.7 or 4.15 did not form germ tubes and 
hyphae, and even at 24 h few cells formed short hyphae. It suggested that compound 4.7 





To evaluate whether 4.7 inhibited the biofilm formation in a time dependent 
manner, compound 4.7 (from 100 µM to 0.2 µM) was added before or at 0, 2, 4, 6, 8 
and 24 h after C. albicans cells have been seeded. At 48 h after seeding, the amount of 
biofilm formation in the wells was determined using XTT assay and the IC50 were 
calculated (Figure 4.6). The effect of 7 on biofilm development was time dependent and 
it inhibited the biofilm formation at different stages. When 4.7 was added before 
seeding the cell, the IC50 was low. It suggested that 4.7 inhibited the adherence of C. 
albicans. And it even could inhibit the biofilm formation after the hyphae had formed, 
but 4.7 could not destroy pre-formed biofilms. Once hyphal formation had been 
initiated farnesol was not able to inhibit the biofilm formation
88
. 
Compounds 4.1-10, 4.13-16 were evaluated for their anticancer activity against 
MIA PACA-2 pancreatic cancer cells. Compound 4.8 and 4.6 exhibited weak anticancer 











Figure 4.4. ORTEP structure for 4.7 generated 
from the X-ray diffraction data 
 
   
 
     
 
Figure 4.5. Time of addition study of 
compound 4.7. 4.7 (from 100 µM to 0.2 µM) 
was added before (-0.5 h) or after (0, 2, 4, 6, 8 
and 24 h) inoculation C. albicans DAY185 into 
96-well microplates. At 48 h after seeding, the 
wells were washed by PBS twice and the 
amount of biofilm formation in the wells was 
determined by XTT assay. The 50% inhibitory 
concentration (IC50) value for biofilm inhibition 
was calculated using GraphPad Prism software 
(GraphPad, La Jolla, CA, USA). All 
experiments were performed in triplicate on 
three replicate experiments in separate dose. 
 
 


















Table 4.1.  
1
H (500 MHz) and 
13














































 waikialoid  A (4.7)  waikialoid  B (4.8) 
position δC, mult. δH (J in Hz) δC, mult. δH (J in Hz) 
1a 44.2, CH2 3.29, td (7.2, 11.6) 43.8, CH2 3.19, m 
1b  3.47, m  3.41, m 
2 24.8, CH2 2.00, m 24.6, CH2 1.98, m 
    2.22, m 
3a 29.4, CH2 1.83, m 29.1, CH2 1.81, m 
3b  2.76, td (6.5, 12.8)  2.75, m 
4 65.8, qC  65.5, qC  
5 28.6, CH2 2.16, m 28.7, CH2 2.12, m 
    2.20, m 
6 43.6, CH 3.00, m 43.0, CH 2.74, m 
7 38.1, qC  38.0, qC  
8 151.3, qC  148.5, qC  
10 140.0, qC  140.9, qC  
11 113.0, qC  112.6, qC  
12 116.7, CH 7.56, d (10.5) 116.9, CH 7.34, d (10.3) 
13 131.7, CH 5.52, d (10.5) 131.8, CH 5.54, d (10.2) 
14 76.4, qC  76.3, qC  
16 153.6, qC  154.6, qC  
17 115.0, CH 6.44, d (8.3) 115.4, CH 6.98, d (8.4) 
18 120.7, CH 6.89, d (8.3) 120.6, CH 6.70, d (8.3) 
19 129.7, qC  124.0, qC  
20 61.8, qC  58.7, qC  
21 58.2, CH 5.55, s 59.7, CH 5.25, s 
22 64.6, qC  64.8, qC  
23 167.1, qC  166.2, qC  
25-NH  7.44, s  7.78, s 
26 174.2, qC  173.7, qC  
27 17.0, CH3 1.68, s 18.2, CH3 1.60, s 
28 26.6, CH3 1.83, s 27.5, CH3 1.76, s 
29 27.4, CH3 1.15, s 27.6, CH3 1.26, s 
30 27.4, CH3 1.28, s 28.9, CH3 1.47, s 
31a 44.6, CH2 3.62, m 45.0, CH2 3.73, m 
31b  3.47, m   
32 25.0, CH2 2.11, m 28.7, CH2 2.12, m 
    2.20, m 
33a 29.9, CH2 1.99, m 29.5, CH2 2.09, m 
33b  2.94, m  2.95, m 
34 68.8, qC  68.5, qC  
35a 30.9, CH2 2.02, m 31.7, CH2 1.99 
35b  2.42, dd (10.5, 12.5)  2.44, dd (12.8, 9.8) 
36 46.9, CH 3.08, dd (10.3, 6.7) 51.2, CH 3.12, dd (17.5, 8.5) 
37 34.2, qC  37.0, qC  
38 141.4, qC  146.8, qC  
39  7.58, s   
40 132.7, qC  139.1, qC  
41 104.6, qC  112.6, qC  
42 117.0, CH 6.40, d (9.3) 116.9, CH 7.48, d (10.3) 
43 129.7, CH 5.58, d (9.8) 131.4, CH 5.61, d (10.3) 
44 75.6, qC  76.3, qC  
46 148.8, qC  154.9, qC  
47 111.0, CH 6.64, d (8.3) 118.4, CH 6.78, d (8.3) 
48 120.1, CH 7.14, d (8.8) 122.8, CH 7.06, d (8.3) 
49 120.4, qC  124.0, qC  
50 103.5, qC  76.9, qC  
51 43.4, CH 5.14, s 52.2, CH 4.46, s 
52 70.4, qC  71.1, qC  
53 168.8, qC  169.5, qC  
56 174.3, qC  174.0, qC  
57 22.4, CH3 1.02, s 27.4, CH3 1.22, s 
58 27.5, CH3 1.26, s 26.4, CH3 1.74, s 
59 27.4, CH3 1.37, s 19.5, CH3 1.25, s 
60 27.4, CH3 1.39, s 28.8, CH3 1.47, s 




Table 4.2.  
1
H (400 MHz) and 
13
C (100 MHz) NMR data for 4.15 and 4.16 (CD3OD) 
 
 asperonol A (4.15)  asperonol B (4.16) 
position δC, mult. δH (J in Hz)   δC,mult. δH (J in Hz) 
1 18.5, CH3 1.78, d (6.8)  18.6, CH3 1.77, d ( 6.7) 
2 130.5, CH 5.73, qd (14.3, 6.8)  129.8, CH 5.66, m 
3 133.2, CH 6.13, m  131.8, CH 6.06, m 
4 133.6, CH 6.13, m  131.8, CH 6.06, m 
5 131.7, CH 6.13, m  132.6, CH 6.06, m 
6 133.0, CH 6.13, m  133.3, CH 6.06, m  
7 136.4, CH 5.55, dd (13.7, 9.0)  138.8, CH 5.46, dd (13.7, 9.0)          
8 46.0, CH 1.95, dddd (9.0, 11.3, 13.0, 3.8)  42.2, CH 2.11, m 
9a 42.9, CH2 1.67, ddd (11.3, 11.3, 11.6)  43.4, CH2 1.16, ddd (11.6, 10, 11.6) 
9b  2.08, ddddd (11.3, 3.8, 3.9, 2.2, 2.2)   1.88, dddd (12.1, 2.0, 3.5, 4.0) 
10 69.7, CH 3.78, dddd (11.6, 3.9, 4.2, 11.4)  66.3, CH 3.95, m 
11a 52.0, CH2 2.45, ddd (11.2, 11.4, 2.5)  43.5, CH2 1.39, ddd (12.0, 11.7, 2.7) 
11b  2.65, ddd (11.2, 4.8, 2.5)   2.16, m  
12 211.7, qC   72.8, CH 3.90, m 
13 49.5, CH 2.25, dq (13.0, 6.5)  41.8, CH 1.28, m                  
14 12.6, CH3 0.93, d (6.7)   16.8, CH3 0.91, d ( 7.0) 
                  
               





a of biofilm inhibition (µM) The MICb of growth inhibition (µM) 
 108.58±3.73 >200 
4.2 93.49±3.62 >200 
4.4 97.34±5.46 >200 
4.5 55.24±2.43 >200 
4.6 43.30±3.53 >200 
4.7 1.40±0.24 >200 
4.8 46.27±1.57 >200 
4.15 32.36±1.98 >200 
4.16 96.94±2.10 >200 
farnesol 128.60±2.60 >200 
aIC50 expressed as the concentration corresponding to 50% reduction of candida biofilm formation. 





4.3 Method and material 
4.3.1 General Methods. 
The melting points were obtained on a Mel-Temp capillary melting point 
apparatus. Optical rotations were measured on a Rudolph Research Autopol III 
automatic polarimeter. UV were measured on Hewlett Packard 8452A diode array 
spectrometer, CD spectra were measured on AVIV circular dichroism spectrometer 
model 202-01. IR was measured on A2 technology nano FTIR and Bruker vector 22 
FTIR spectrometer respectively. NMR data were obtained on Varian VNMR 
spectrometers (400 and 500 MHz for 
1
H, 100 and 125 MHz for 
13
C) with broad band 
and triple resonance probes at 20 ± 0.5 
°
C.  Electrospray-ionization mass spectrometry 
data was performed on an Agilent 6538 high-mass-resolution QTOF mass spectrometer. 
Crude extract was separated on prepacked silica cartridges using Biotage Isolera 
chromatography system. HPLC separations were performed on a Shimadzu system 
using a SCL-10A VP system controller and Gemini 5 µm C18 column, (110 Å, 250 x 
21.2 mm) with flow rates of 1 to 10 mL/min.  X-ray diffraction data (4.7) were 
collected on a Bruker APEX II CCD system equipped with a Cu ImuS micro-focus 
source with Quazar MX optics (λ = 1.54178 Å), X-ray data (4.15) were collected using 
a diffractometer with a Bruker APEX ccd area detector and graphite-monochromated 
Mo K radiation (λ = 0.71073 Å).  All solvents were of ACS grade or better. 
4.3.2 Organism Collection, Identification, and Culture Methods.  
  A ~1 g portion of a soil sample collected near Waikiki Beach (Honolulu, Hawaii) 
in July, 2010 was placed in autoclaved H2O (10 mL) and diluted 10- and 100-fold.  
Aliquots (300 μL) of the soil suspensions were spread over the surfaces of 10 cm 




were maintained at 25 °C for four weeks.  Colonies were selected from the plates and 
transferred to fresh Petri plates containing czapek agar with chloramphenicol (50 mg/L).  
This process was repeated for each isolate until pure fungal cultures were established.  
Pure isolates were transferred to new Petri plates containing czapek agar (without 
chloramphenicol) and after 2-3 weeks of incubation at 25 °C, pieces of the agar with 
mycelia (~0.5 cm
2
) were cut and placed in cryogenic storage tubes with sterile glycerol-
H2O (15:85).  The tubes were then stored at -80 °C until the fungus was needed for 
scale-up studies.  The fungus was identified as Aspergillus sp. based on sequence 
analysis of its large-ribosomal-subunit ITS1 region of the rDNA gene.   
For the static preparative-scale grow-up, fungal mycelia and spores were 
inoculated into 50 mL potato-dextrose media and grown for one week with shaking 
(125 rpm).  The cellular material was placed in a sterile Falcon tube and mixed by 
vortexing for several minutes to create a uniform fungal cell/spore suspension.  Aliquots 
(500 µL) of the fungal suspension were used to inoculate 110 Erlenmeyer flasks (1 L) 
containing autoclaved media (0.1 g rice, 0.1 g oatmeal, 0.1 g cornmeal, 0.32 g nutrient 
broth, ~0.5 g vermiculite, and 50 mL of deionized H2O).  Culture vessels were 
maintained on the bench-top at 25 °C for 20 days.  
For the shaking preparative-scale grow-up, aliquots (500 µL) of the fungal 
suspension were used to inoculate 12 L autoclaved media (potato-dextrose) in 20 L 
fermentator. The culture was fermented at 25°C for 14 days.   
4.3.3 Extraction and Isolation.  
The static scale up culture was extracted by ethyl acetate overnight and the organic 




50% to 100% hexane in methylene chloride for 8 min then 100% methylene chloride for 
8 min. 0% to 20% methylene chloride in MeOH for 20 min gradient) and yielded four 
fractions. The fractions Fr.2 (500 mg) eluted under 18% methylene chloride in MeOH 
was subjected to preparative HPLC (mobile phase 40% to 100% MeOH in H2O). 
Subfraction Fr. 11-14 were eluted under 80% MeOH and further purified by semi-prep 
HPLC provided compound 4.1 (1 mg), 4.2 (1.8 mg), 4.3 (20 mg), 4.4 (1 mg), 4.5 (1 mg), 
4.6 (1 mg), 4.7 (4 mg) and compound 4.8 (1 mg), 4.11 (2 mg), 4.12 (0.3 mg), 4.13 (13 
mg) and 4.14 (2.2 mg) 
The liquid scale up culture was extracted with ethyl acetate with 1:1 ratio. The 
organic layer was recovered and the solvent was removed under vacuum.  The resulting 
organic extract was separated by silica gel (mobile phase 50% to 100% hexane in 
methylene chloride for 8 min then 100% methylene chloride for 8 min, 0% to 20% 
methylene chloride in MeOH for 20 min gradient) using Isolera. Then the 15% 
methylene chloride in MeOH fraction (660 mg ) was subjected to the silica gel 
separation under 0% to 50% methylene chloride in MeOH gradient and a fraction (320 
mg) under 12% methylene chloride in MeOH was subjected to prep-HPLC (mobile 
phase 30% to 100% MeOH) yielded compound 4.9 (12 mg), 4.10 (10 mg), 4.15 (9.5 mg) 
and 16 (61.8 mg) 
4.3.4 Waikialoid A (4.7) 
Yellow, crystalline solid; mp: 174-176 °C, [α]
 21
D –12.0 (c 0. 15, MeOH); UV 
(MeOH) λmax (log ε) 206 (4.99), 264 (4.75), 302 (4.39) nm; CD (MeOH; Δε) 231(+29.2), 







data, see Table 4.1; HRESIMS m/z 875.4119 [M+H]
+




 4.3.5 Waikialoid B (4.8) 
Yellow, amorphous solid; [α]
 21
D 28.5 (c 0.035, MeOH); UV (MeOH) λmax (log ε) 
206 (4.74), 264 (4.29) nm; CD (MeOH; Δε) 226 (+16.3), 243 (-18.2), 320 (-8.7); IR νmax 






C NMR data, see Table 4.1; HRESIMS m/z 
905.3827  [M-H]
-
(calcd for C52H53N6O9, 905.3874). 
4.3.6 Asperonol A (4.15) 
  White, crystalline solid; mp: 115-117 °C, [α]
21
D 11.4 (c 0.035, MeOH); UV 
(MeOH) λmax (log ε) 202 (4.38), 266 (4.81) nm; CD (MeOH; Δε) 266 (10.9), 293(-9.9) ; 






C NMR data, see 
Table 4.2; HRESIMS m/z 243.1378 (calcd for C14H20O2Na , 243.1361). 
4.3.7 Asperonol B (4.16) 
White, amorphous solid; [α]
21
D 97.1 (c 0.175, MeOH); UV (MeOH) λmax (log ε) 






C NMR data, see 
Table 4.2; HRESIMS m/z 221.1543 [M-H]
-
  (calcd for C14H21O2 , 221.1542). 
4.3.8 Preparation of Mosher Ester Derivatives 4.15a and 4.15b.  
Compound 4.15 was transferred into two NMR tubes (0.25 mg each, 0.0011 
mmol) and totally dried under vacuum then treated with dry pyridine (0.4 mL each) and 
0.5uL (0.00267 mmol) of (S)-(+)-R-methoxy-R-(trifluoromethyl)-phenylacetyl chloride 
(MTPA chloride) and (R)-(-)-R-methoxy-R-(trifluoromethyl) phenylacetyl chloride 
reagent individually. The mixture was reacted at RT for 4 h. The completion of reaction 
was monitored by 
1
H-NMR. Two derivatives 4.15a and 4.15b of compound 4.15 were 
obtained. The 
1




H COSY spectrum was 




4.3.9 S-MPTA ester of derivative (4.15a) of 4.15
 
1
H NMR (500 MHz, pyridine)  δ = 6.12 - 6.36 (4H, m, H-3, H-4, H-5, H-6), 5.74 
(1H, dd, J = 14.4 Hz, J = 7.1 Hz, H-2), 5.44 - 5.57 (2H, m, H-3, H-10), 3.11 (1H, d, J = 
10.8 Hz, H-11), 2.79 (1H, t, J = 12.2 Hz, H-11), 2.20 - 2.34 (2H, m, H-8, H-13), 2.06 - 
2.16 (1H, m, H-9),1.76 - 1.87 (1H, m, H-9), 1.69 (3H, d, J = 6.4 Hz, H-1), 1.06 (3H, d, J 
= 6.4 Hz, H-14). 
4.3.10 R-MPTA ester of derivative (4.15b) of 4.15 
  
1
H NMR (500MHz, pyridine)  δ = 6.13 - 6.39 (4H, m, H-3, H-4, H-5, H-6), 5.69 
- 5.80 (1H, m, H-2), 5.45 - 5.59 (2H, m, H-3, H-10), 3.04 (1H, ddd, J = 13.0 Hz, J = 5.1 
Hz, J = 2.0 Hz, H-11), 2.65 (1H, t, J = 12.0 Hz, H-11), 2.32 (1H, dt, J = 12.2 Hz, J = 5.1 
Hz, H-9), 2.25 (1H, dt, J = 12.1 Hz, J = 6.4 Hz, H-13), 2.13 (1H, tdd, J = 11.8 Hz, J = 
8.7 Hz, J = 2.9 Hz, H-8), 1.86 - 1.96 (1H, m, H-9), 1.69 (3H, dd, J = 6.6 Hz, J = 1.2 Hz, 
H-1), 1.07 (3H, d, J = 6.4 Hz, H-14). 
4.3.11 X-ray Crystal Structure Analysis. 
X-ray diffraction data of 4.7 was collected on a Bruker APEX II CCD system 
equipped with a Cu ImuS micro-focus source with Quazar MX optics. A total of 67703 
data were measured in the range 3.54 < θ < 67.16° using and oscillation frames. The 
data were merged to form a set of 7859 independent data with R(int) = 0.0272 and a 
coverage of 97.6 %. A total of 635 parameters were refined against 21 restraints and 
7859 data to give wR(F
2
) = 0.0845 and S = 1.005 for weights of w = 1/[σ2 (F2) + 
(0.0530 P)
2




] / 3. The final R(F) was 0.0316 for the 
7855 observed, [F > 4σ(F)]. The calculated minimum and maximum transmission 




direct methods and refined by full-matrix least-squares methods on F2. The final 
anisotropic full-matrix least-squares refinement on F2 with 675 variables converged at 
R1 = 3.16%, for the observed data and wR2 = 8.45% for all data. The goodness-of-fit 
was 1.005. The largest shift/s.u. was 0.033 in the final refinement cycle. The final 
difference map had maxima and minima of 0.343 and -0.281 e/Å3. On the basis of the 
final model, the calculated density was 1.309 g/cm3 and F(000), 984 e-. 
X-ray diffraction data of 4.15 was collected on a Bruker APEX ccd area detector and 
graphite-monochromated Mo K radiation (λ = 0.71073 Å). A total of 4287 data were 
measured in the range 2.36 < θ< 22.99° using φ and ω oscillation frames, 1000 of which 
were independent R (int)=0.1127. The structure was solved by direct methods and 
refined by full-matrix least-squares methods on F2. Hydrogen atom positions were 
initially determined by geometry and refined by a riding model. Non-hydrogen atoms 
were refined with anisotropic displacement parameters. 
4.3.12 Assay for Growth Inhibition and Biofilm Formation.  
The effect of compounds on the growth of C.albicans DAY185 was tested using 
the method described in the guidelines of CLSI M27-A2 (NCCLS 2002). Biofilm assay 
was performed as described 
89
 with the following modifications. Strain C. albicans 
DAY185 were cultured in BHI medium (Brain Heart Infusion, Becton Dickinson and 
company, MD, USA) at 37 ºC overnight and were washed with sterile PBS (phosphate-
buffered saline, pH 7.4, EMD chemicals Inc., NJ, USA) and resuspended in RPMI 1640 
medium (Sigma Chemical Corporation, MO, USA) buffered to pH 7.0 with MOPS (3-
(N -morpholino) propanesulfonic acid, 0.165 M, Sigma). The compounds were prepared 




serially diluted 2-fold from highest concentration of 200 µM with RPMI 1640 plus 
MOPS medium. Farnesol was used as positive control 
90
. One hundred microliter of 
yeast suspension (2.5×103  cells/mL) containing the diluted compounds (from 200 µM 
to 6.25 µM) or DMSO (v/v 1%) was added in 96-well microplate (Costar 3370, Corning 
Incorporated, NY, USA). After 48 h of incubation at 37 ºC, the viability of yeast was 
measured using the XTT (tetrazolium salt 2, 3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-
(phenylamino)-carbonyl-2H-tetrazoliumhydroxide, Sigma) assay. In brief, yeast cells 
were treated with 0.1 mg/mL XTT at 37 ºC for 1 h. The absorbance was taken at 490 
nm using a microplate reader (Infinite M200, Tecan Group Ltd., Männedorf, 
Switzerland). The minimum inhibitory concentration (MIC) for growth was defined as 
the lowest antifungal concentrations that caused ≥80% reduction in the metabolic 
activity. To measure the biofilm formation, the medium was aspirated and wells were 
washed twice with sterile PBS to remove non-adherent cells, and 100 µL RPMI 1640 
plus MOPS medium was added into each well. The prewashed biofilms were measured 
using XTT assay 
91
. All experiments were performed in triplicate on three separate 
occasions. The 50% inhibitory concentration (IC50) value for biofilm inhibition was 
calculated using GraphPad Prism software (GraphPad, La Jolla, CA, USA). 
4.3.13 Hyphae Formation Assay. 
  C. albicans DAY185 was grown in BHI medium at 37 ºC overnight. The cells 
were washed and suspended using PBS (pH 7.4, EMD). Cells were seeded in a 96-well 
plate at 1×106 cells/well and incubated at 37 ºC for 1 h. Wells were washed twice with 
sterile PBS to remove non-adherent cells. µRPMI 1640 (Sigma) containing 2% glucose 




and the plate were incubated at 37 ºC for 24 h. Farnesol was used as positive control 
90
.The yeast cells were observed under a phase contrast microscope at 2.5, 6 and 24 h 
89
.  
4.3.14 Time of addition assay.  
Based on the biofilm formation assay, 4.7 (from 100 µM to 0.2 µM) was added 
before or at 0, 2, 4, 6, 8 and 24 h after seeding to C. albicans DAY185 culture in a 96-
well microplate. At 48 h after seeding, the wells were washed by PBS twice and the 
amount of biofilm formation in the wells was determined using XTT assay 
92
. The 50% 
inhibitory concentration (IC50) value for biofilm inhibition was calculated using 
GraphPad Prism software (GraphPad, La Jolla, CA, USA). All experiments were 











Chapter 5 Fungal biofilm inhibitors from a human oral microbiome-
derived bacterium 
This chapter is adapted from publication that is currently submitted. 
5.1 Introduction 




 yet it is 
home to amazingly large and diversified assemblage of microbial species.
94
  It is 
estimated that in excess of 1.9×10
4
 bacterial phylotypes occupy the mouth
95
 forming a 
complex community that is dominated by Firmicutes, Proteobacteria, Bacteroidetes, 
Actinobacteria, and Fusobacteria.
96
 Certain fungi including Candida spp. are also 
resident members of the mouth, although these microbes tend to be numerically less 
abundant in healthy adults.
97
 
Streptococcus mutans is one of the perennial members of the oral microbial 
community.
98
  Substantial interest in this microbe has evolved due in part to its ubiquity, 
as well as evidence linking S. mutans to the development of dental caries.
99
 However, 





techniques of caries-associated microbial assemblages have called some of these 
assertions into question.  Regardless, S. mutans is an important component of the oral 





 and mammalian cells.
103
 
Although there is an abundance of published reports illustrating the extent to 
which bacteria and fungi are capable of interacting with other microorganisms within 
their vicinity,
104
 the majority of biomolecules responsible for influencing these 









roles in the intraspecies and interspecies interactions involving microbiome bacteria and 
humans
105
 and our group has taken an active role pursuing the identities of these 
chemical agents.  We had previously reported that S. mutans UA159 generated the 
unique secondary metabolite mutanobactin A (5.1),
106
 which inhibited the 
morphological switch of pathogenic Candida albicans from a yeast to a filamentous 
morphology.
107
  Several questions emerged from that study that included 1) what is the 
absolute configuration of all the stereogenic centers in 5.1, 2) what are the biosynthetic 
precursors that contribute to building this polyketide-non-ribosomal-peptide molecule, 
and 3) what are the structures of the analogues of 5.1?  In this study, we have addressed 
each of these issues, as well as examined the biological impact of mutanobactins on the 
ability of pathogenic C. albicans to form biofilms.  The formation of biofilms by 
Candida spp. is a topic of significant medical relevance
108
 because biofilms serve as 
reservoirs for antibiotic-resistant persister cells, which are key factors in the 
development of therapeutically-recalcitrant and life-threating yeast infections.
109
 
5.2 Results and discussion 
A sample taken from the ethyl-acetate-soluble material obtained from 
partitioning 40 L of S. mutans UA159 culture was analyzed by reversed-phase LC-
ESIMS (positive mode).  This revealed a group of three new peaks with retention times 
and mass-to-charge ratios similar to 5.1 (m/z 743 [M + Na]
+
, tR 24.6 min).  The three 
compounds exhibited base peaks at m/z 757 [M + Na]
+
 (tR 25.8 min), 743 [M + Na]
+
 (tR 
24.6 min), and 721 [M + H]
+
 (tR 24.9 min).  In light of the substantial similarity between 
the LC-ESIMS properties of these compounds and 5.1, we suspected that these peaks 









purification and structure characterization (repeated HP20SS column chromatography 
by changing column size and elute gradient and reversed-phase HPLC). 
HRESIMS analysis of mutanobactin B (5.2) provided a pseudomolecular ion 
with m/z 757.4298 that corresponded to a molecular formula of C37H62N6O7SNa ([M + 
Na]
+
, calcd 757.4298).  Compared to 5.1, this indicated that compound 5.2 possessed 
one additional carbon and two additional hydrogen atoms.  Although the 
1
H NMR data 
for 5.2 (Table 5.1) were nearly superimposable with those for 5.1, we observed a subtle 
shift in the resonances appearing in the highfield region (~1.0 ppm) of the spectrum 
(note: upon further scrutiny, we have found it necessary to reassign some of the carbon 
and proton resonances in the hydrocarbon tail of 5.1; refer to Table A4, for details of 
these changes). In addition, 
13
C NMR (Table 5.1) revealed a new carbon resonance at δC 








H TOCSY, we traced the spin system 
originating from the hydrogens (δH 0.78, H-18) attached to C-18 to a series of protons at 
δH 8.01 (NH-15) 3.75 (H-15), 2.19 (H-16), 0.79 (H-19), 1.35 (H-17a), and 1.02 (H-17b) 








C HMBC NMR data, which confirmed that the Val in 5.1 was 
replaced by an Ile in 5.2 (Figure. 5.1).  Further examination revealed that all other 
portions of the planar structure of 5.2 remained unchanged relative to compound 5.1. 
Mutanobactin C (5.3) afforded a pseudomolecular ion at m/z 743.4138 that 
corresponded to a molecular formula of C36H60N6O7SNa ([M+Na]
+
, calcd 743.4142).  
In addition to sharing the same molecular formula as 5.1, the 
13
C NMR data for 5.1 and 

















possessed the same planar structure as 5.1.  But upon closer scrutiny, several subtle 
changes in chemical shifts for protons H-21a/b (Δ = -0.20 and 0.24 ppm), H-23a/b (Δ = 
-0.38 and -0.07 ppm), H-24 (Δ = -0.19 ppm), and H-25(Δ = -0.19 ppm) were observed 
(Table 5.1).  Thus, it was concluded that 5.3 was a diastereomer of 5.1 with the 
configuration(s) of one or more stereogenic carbons having been altered in the vicinity 
of the aforementioned protons. 
High resolution ESIMS of mutanobactin D (5.4) revealed that this metabolite 
possessed a molecular formula of C37H64N6O8Na ([M+Na]
+
, m/z of 743.4681, calcd 
743.4683). The absence of the sulfur atom signified that the 1,4-thiazepan-5-one system 
in 5.1-5.3 was not present in 5.4.  The loss of this substructure was supported by 
















C HMBC experiments), which showed that key resonances 
attributable to the Ile, Ala, Pro, and Val residues and hydrocarbon tail remained intact, 
but the 1,4-thiazepan-5-system was missing.  Instead, a new spin set consisting of 
protons at δH 8.46 to 3.80, 1.52 and 0.85 was detected by TOCSY leading to the 
identification of an α-aminobutyric acid (Aaba) residue in 5.4.  A second spin set with 
protons at δH 2.65, 3.98, 3.38, and 4.70 (exchangeable) was identified that was 
attributed to a hydroxyglycine residue. HMBC data indicated that one of the 
hydroxyglycine carbons (δC 66.7, C-25) was attached to the C-26 methine (δC 61.7), 
which served as the junction between the C-27 (δC 166.3) and C-28 (δC 204.5) 
carbonyls (Figure. 5.1). Protons (δH 2.65, H-24a and 3.38, H-24b) attached to the other 
hydroxyglycine carbon (δC 42.1, C-24) exhibited 
3
JH-C coupling with the carbonyl of the 









methine (δH 3.80, H-20) coupled (
3
JH-C) with the Ala carbonyl (Figure. 5.1).  Therefore, 




















C NMR data for 5.2-5.4 (500 and 100 MHz in DMSO-d6) 
 
position 
5.2  5.3  5.4 
δC δH, mult. (J in Hz)  δC δH, mult. (J in Hz)  δC δH, mult. (J in Hz) 
1 50.3, CH 4.43 ddd (3.6, 9.3, 11.0)  50.6, CH 4.43, m  52.3, CH 4.21, m 
2a 40.4, CH2 1.44, m  40.2, CH2 1.59, m  40.5, CH2 1.45, m 
2b  1.82, ddd (3.6, 10.5, 13.9)   1.52, m   1.71 
3 24.2, CH 1.60, m  24.4, CH 1.60, m  24.5, CH 1.43, m 
4 20.8, CH3 0.82, d (6.6)  21.1, CH3 0.84, d (6.5)  21.6, CH3 0.91, d (6.4) 
5 23.5, CH3 0.92, d (6.4)  23.1, CH3 0.92,d (6.5)  23.6, CH3 0.81, d (6.4) 
6 170.5, C   170.2, C   172.0, C  
7 48.1, CH 4.51, q (6.7)  47.5, CH 4.46, m  47.5, CH 4.25, m 
8 17.6, CH3 1.17, d (6.7)  16.7, CH3 1.20, d (6.8)  15.1, CH3 1.20, d (6.9) 
9 170.0, C   171.6, C   171.1, C  
10 61.2, CH 4.11, dd (3.4, 8.7)  61.2, CH 4.17, dd (3.7, 8.7)  60.0, CH 4.35, brd (7.0) 
11a 29.6, CH2 1.70, m  29.6, CH2 1.87, m  29.4, CH2 1.98, m 
11b  2.13, m   2.12, m   2.06, m 
12a 24.5, CH2 1.90, m  24.2, CH2 1.90, m; 1.78, m  23.6, CH2 1.76, m 
12b        1.98, m 
13a 46.8, CH2 3.42, m  47.2, CH2 3.51, m  46.5, CH2 3.54, m 
13b  3.68, m   3.78, m   3.91, brt (8.9) 
14 171.6, C   171.1, C   170.5, C  
15 56.7, CH 3.75, dd (8.7, 10.0)  58.8, CH 3.92, t (6.6, 7.0)  58.2, CH 4.05, brt (9.9) 
16 31.5, CH 2.19, m  29.2, CH 2.21, m  29.5, CH 2.13, m 
17a 21.4, CH2 1.35, m  19.7, CH3 0.92, d (6.7)  19.8, CH3 0.90, d (6.5) 
17b  1.02, m       
18 10.0, CH3 0.78, m  18.5, CH3 0.93, d (6.7)  19.4, CH3 0.97, d (6.6) 
19 16.2, CH3 0.79, d (6.8)  170.1, C   172.0, C  
20 168.9, C   56.3, CH 4.46, m  56.4, CH 3.80, td (2.4, 7.4) 
21a 52.3, CH 4.85, m  26.2, CH2 2.43, m  23.8, CH2 1.52, m 
21b     2.95, dd (9.9, 15.3)    
22a 28.4, CH2 2.21, brd 16.3  169.8, C   10.3, CH3 0.85, t (7.4) 
22b  3.19, dd (8.2, 16.3)       
23a 170.3, C   40.7, CH2 3.17, m  172.5, C  
23b     3.35, m    
24a 43.8, CH2 2.76, m  41.1, CH 3.44, m  42.1, CH2 2.65, brd (13.7) 
24b  3.28, m      3.38, m 
25 40.9, CH 3.25, m  62.8, CH 4.06, d (8.9)  66.7, CH 4.18, m 
26 61.7, CH 3.88, d (9.4)  166.3, C   61.7, CH 3.98, d (10.4) 
27 167.7, C   202.7, C   166.3, C  
28a 203.8, C   40.8, CH2 2.37, m  204.5, C  
28b     2.43, m    
29a 41.3, CH2 2.33, m  23.0, CH2 1.45, m  40.1, CH2 2.23, m 
29b  2.44, dd (8.4, 11.4)      2.35, m 
30 23.0, CH2 1.45, m  28.4, CH2 1.17, m  22.5, CH2 1.36, m 
31 28.5, CH2 1.20, m  28.7, CH2 1.22, m  28.4, CH2 1.16, m 
32 28.6, CH2 1.22, m  28.9, CH2 1.22, m  28.6, CH2 1.20, m 
33 28.9, CH2 1.22, m  28.7, CH2 1.22, m  29.0, CH2 1.21, m 
34 28.7, CH2 1.23, m  31.3, CH2 1.22, m  28.7, CH2 1.22, m 
35 31.3, CH2 1.23, m  22.1, CH2 1.24, m  31.2, CH2 1.22, m 
36 22.1, CH2 1.23, m  14.0, CH3 0.85, t (6.8)  22.1, CH2 1.22, m 
37 14.0, CH3 0.85, t (6.8)     13.9, CH3 0.84, t (6.8) 
1-NH  8.55, d (9.1)   8.70. brs   8.12, d (4.5) 
7-NH  7.74, d (6.6)   7.91, d (4.9)   9.05, brs 
15-NH  8.01, d (8.3)   7.35, brs   7.63, d (9.3) 
20-NH     7.74, d (6.3)   8.46, d (2.6) 
21-NH  7.20, d (7.6)       
23-NH     7.69, m    
24-NH  7.93, dd (6.2, 8.2)      7.81, dd (2.5, 14.1) 











With the planar structures of metabolites 5.2-5.4 established, we proceeded to 
investigate the absolute configuration of each compound.  Several approaches were 








H NOESY.  In 
addition, insights gained from our structure analyses of 5.2-5.4 provided a good 
opportunity to re-evaluate the yet undefined configuration of stereogenic centers C-20, 
C-24, and C-25 in 5.1.
107
  Numerous attempts to produce suitable crystals of 5.1-5.4 for 
X-ray analysis failed with gels or amorphous precipitates consistently formed. 
Marfey’s reagent, 1-fluoro-2,4-dinitrophenyl-5-L-alanine amide reacts with the 
optical isomers of amino acids to form diastereomers which can be separated by HPLC 
(Schme 5.1). The hydrolysates of 5.2, 5.3, and 5.4 were analyzed by HPLC and the 
products compared to derivatized amino acid standards for the D and L forms of Aaba, 
Ala, Ile, Leu, Pro, and Val.  This enabled us to confirm that compound 5.2 contained L-
Leu, D-Ala, L-Pro, and L-Ile residues; compound 5.3 contained L-Leu, D-Ala, L-Pro, 























experiment and this had provided us with a substantial number of NOE cross peaks.  
However, the lack of additional mutanobactin congeners at that time prohibited us from 
confidently assigning the absolute configuration of C-22, C-24, and C-25. Now with 
diastereomer 5.3 in hand, determining the absolute configuration of each stereogenic 
carbon became relatively straightforward.  We identified three key elements that made 
this analysis possible: first, both 5.1 and 5.3 exhibited large (anti configuration) vicinal 
couplings between H-24 and H-25 (J = 9.8 and J = 8.9 Hz, respectively); second, the 
anti relationships between H-24 and H-25 were further substantiated by the absence of 
NOE cross peaks between these protons in 5.1 and 5.3; and third, compounds 5.1 and 
5.3 exhibited dramatically different trans-annular NOE cross peaks between their 
respective 1,4-thiazepan-5-one rings and the amide protons of the D-Ala residues. In the 
case of compound 5.1, both H-21a and H-21b exhibited trans-annular NOE cross peaks 
with the D-Ala NH (Figure. 5.2).  In contrast, compound 5.3 H-23a and H-23b 
produced strong NOE correlations to the D-Ala NH (Figure. 2).  These data provided 
compelling evidence that the 1,4-thiazepan-5-one system was rotated roughly 180º in 
5.3 relative 5.1.  Accordingly, we determined that 5.1 possessed a 24R*,25R* relative 
configuration and 3 has a 24R*,25S* relative configuration. 
Further support for this hypothesis was obtained via computer-generated lowest 
energy calculations performed on 5.1 and 5.3 using a MM2 force field parameter set 
(Chembio 3D).  In addition to delivering in silico validation of the configuration 
assignments, we observed striking differences in the predicted orientations of the Cys 










in which Cys H-20 of 1 produced NOE cross peaks with the 1,4-thiazepan-5-one ring 
protons H-23 and H-25, as well as the L-Val H-17/H-18.  In contrast, inversion of the 
1,4-thiazepan-5-one ring in 3 resulted in Cys H-20 adopting a pseudoequitorial 
orientation (Figure. 5.2). This led to the absence of NOE cross peaks between Cys H-20 
and H-23/H-25. Taking into account the configuration assignments for C-24/C-25, the 
NOE cross peaks involving the C-20 methine protons, NOESY data between protons 
within the 1,4-thiazepan-5-one ring and the surrounding amino acid residues, as well as 
the trans-annular NOE correlations (Figure. 5.2), we refined the absolute configuration 
of 5.1 as 1S,7R,10S,15S,20R, 24R,25R and its C-25 epimer 5.3 as 1S,7R,10S,15S,20R, 
24R,25S. 




H NOESY data that were nearly identical those 
afforded by 5.1. In light of the significant similarities between these compounds, 5.2 
was deduced as having a 1S,7R,10S,15S,16S,21R, 25R,26R absolute configuration.  
Data obtained from NOESY and long-range 
2-3
JH-C experiments with 5.4 proved 
inconclusive for discerning the absolute configuration of C-25 and C-26.  However, 
results from the Marfey’s experiment (vide supra) enabled us to deduce the absolute 
configuration of the other stereogenic carbons as 1S,7R,10S,15S,20S. 
Previously, we had predicted that the mutanobactins were derived from a hybrid 
polyketide-nonribosomal-peptide-synthetase pathway.
106
 Upon examination of the 
biosynthetic gene cluster, it was proposed that seven amino acids would be incorporated 
into the mutanobactins; however, evidence gathered from the chemical analysis of 5.1 
revealed that only six amino acid residues were readily apparent.
107
  We speculated that 










may have been derived from the incorporation and subsequent rearrangement of Gly 








N]Gly showed significant isotope incorporation at N-23, C-23, and C24 (Table 




N]Asp was added 
(data not shown).  These data indicated that Gly is fully integrated into the 
mutanobactin skeleton while Asp is either not incorporated or latter excised during the 
biosynthetic process (Figure. 5.3).  Despite these new insights, the origins of C-25 and 
C-26 in 5.1 remained unknown.  Suspecting that the polyketide synthase could 





C]acetate. Addition of [1-
13
C]acetate to the 
culture medium resulted in substantial enhancement of the NMR signals for C-26, C-27, 
C-29, C-31, C-33, and C-35 in compound 5.1 (Table 5.2 and Figure.5.3).  In contrast, 
incorporation of [2-
13
C]acetate to the growth medium led to enhancement of the NMR 
resonances for C-25, C-28, C-30, C-32, and C-34 in compound 5.1 (Table 5.2 and 
Figure. 5.3).  Therefore, head-to-tail condensation of six acetate units is believed to be 
responsible for generating these 12 carbon atoms in the mutanobactin skeleton. We 
propose that the mutanobactins are generated via the sequential addition of L-Leu, L-
Ala (later epimerized), L-Pro, L-Val (or L-Ile), L-Cys (or L-Aaba), and L-Gly to the 
polyketide chain.  In view of the structure of metabolite 5.4, we suspect that closure of 
the 20-member macrocycle precedes formation of the 1,4-thiazepan-5-one ring.  This 
process may occur by deprotonation of the β-keto amide methylene (C-25, pKa ~10.8 










Gly thioester carbonyl and release the metabolite from the synthetase.  Next, formation 
of the 1,4-thiazepan-5-one ring could proceed via either reduction of the C-24 carbonyl 
followed by nucleophilic attack of the thiol on the secondary alcohol or direct attack of 
the thiol on the C-24 carbonyl.  While these mechanisms present certain challenges and 
should be regarded with caution, both help illustrate how inflection of the 1,4-
thiazepan-5-one ring systems in 5.1 and 5.3 may arise. 
 








C couplings (J(C, C)) for isotope 




















J (C-C, N-C) (Hz) 
22 170.4 1.6 1.0  
23 43.7 1.5 1.8 35.0, 9.5 
24 41.0 1.3 1.1 35.0 
25 61.7 1.2 25.6  
26 167.7 15.7
c
 0.7  
27 203.8 17.1 0.7  
28 41.4 1.0 20.2  
29 23.1 15.3 1.0  
30 28.5 1.3 21.5  
31 28.7 15.4 1.0  
32 28.9 1.0 19.6  
33 28.8 13.9 0.8  
34 31.3 0.7 15.6  
35 22.1 13.0 0.7  
36 14.0 2.2 50.4  
a
The DMSO signal (49.5ppm) was used as a reference 
b
Enrichment ratios (ER) were calculated by comparison to signals from the unlabeled 
compound  
c
Resonances in bold were determined as having been enriched 
 
We had previously shown that the S. mutans mutant lacking the mutanobactin 
gene cluster was unable to block filament formation of pathogenic Candida albicans in 
a co-culture system.
107
  Furthermore, addition of 5.1 to C. albicans under filament 
promoting conditions suppressed the formation of mycelia. Although the linkage 
between filament formation and pathogenesis is under debate,
111
 it is well documented 
that it is one of several essential steps in biofilm formation.
112










are often encountered in polymicrobial biofilm communities.
113
  While ensconced in 
biofilms, pathogens such as C. albicans have diminished susceptibilities to antibiotics 
and are challenging targets for in vivo elimination.
114
  We tested 5.1-5.4 in an assay 
designed to determine if the mutanobactins could inhibit C. albicans biofilm formation.  
Compound 5.4 was found to be the most potent inhibitor of biofilm formation with an 
IC50 value of 5.3 µM.  In comparison, farnesol, a well-known and widely tested 
inhibitor of C. albicans biofilm formation,
115
 had a much higher IC50 value of 1.4×10
2
 
µM.  Compounds 5.1 and 5.2 showed reduced activities with IC50 values of 3.4×10 and 
9.1×10 µM, respectively.  Metabolite 3 showed no activity at concentrations up to 200 
µM.  This is rather remarkable since the only variation between compounds 5.1 and 5.3 
is the substitution of a L-Ile residue in 5.3 for the L-Val in 5.1.  It is noteworthy that 
none of the compounds reduced the viability of C. albicans (tested over a range from 
6.25 to 200 µM), which indicates that the mutanobactins may selectively exert their 
effects against a biofilm-formation-specific target (e.g., filament formation). 
Table 5.3.  Biofilm formation inhibition and MIC values of metabolites 1-4 and 
farnesol against C.albicans Day185 
Compound 
Biofilm formation inhibition 




(MIC in µM) 
5.1 3.4×10 ± 1.3 >200 
5.2 9.1×10 ± 1.6 >200 
5.3 >200 >200 
5.4 5.3 ± 0.9 >200 
Farnesol 1.4×10
2
 ± 1.2 >200 
a
IC50 expressed as the concentration of compound required to cause a 50% reduction in biofilm 
formation 
5.3 Conclusions 
The human microbiome contains an abundance of taxonomically diverse bacteria, a 










to expect that many of these microbial-derived compounds will have evolved unique 
biological functions that make them important factors for maintaining our wellbeing.  
The mutanobactins provide a foretaste of the intriguing roles and potential therapeutic 
applications of compounds biosynthesized by bacteria living in and on the human body. 
 
 


































H NOESY correlations observed for 5.1-5.3.  For each compound, 
trans-annular NOE correlations from the 1,4-thiazepan-5-one rings to the amid D-Ala 
7-NH are shown on the left side of the figure.  On the right, close-up views are shown 
of NOE correlations involving other 1,4-thiazepan-5-one ring protons. The black 

























N]glycine in mutanobactin A (5.1). 
5.4 Experimental section 
5.4.1 General experimental procedures 
Optical rotations were measured on a Rudolph Research Autopol III automatic 
polarimeter. UV data were measured on Hewlett Packard 8452A diode array 
spectrophotometer, IR was measured on A2 Technology Nano FTIR.  NMR data were 
obtained on Varian VNMR spectrometers (400 and 500 MHz for 
1
H, 100 and 125 MHz 
for 
13
C) with broad band and triple resonance probes at 20 ± 0.5 
°
C.  LC-ESIMS data 
were collected using a Thermo-Finnigan Surveyor LC system and a Finnigan LCQ 
Deca mass analyzer. HRESIMS data were obtained by electrospray ionization 
employing an Agilent 6538 UHD Accurate-Mass Quadrupole TOF mass analyzer.  
Flash chromatography was performed on a Biotage Isolera One using a 50 g C18 
column with a flow rate of 50 mL/min. HPLC separations were performed on a 
Shimadzu system using a SCL-10A VP system controller and Gemini 5µm C18 column, 
(110Å, 250 x 21.2 mm) with flow rates of 1 to 10 mL/min.  All solvents were of ACS 










5.4.2 Fermentation, extraction, and purification of mutanobactins 
Streptococcus mutans UA159 was prepared by inoculating 40 L of brain-heart 
infusion broth with 100 mL of an overnight stationary S. mutans UA159 culture.  The 
culture was incubated under microoxic conditions at 37 °C for 96 h.  The culture was 
extracted three times with equal volumes of ethyl acetate, which was evaporated in 
vacuo to generate the S. mutans UA159 extract.  The crude extract (35 g) was separated 
into five fractions by HP20SS column chromatography (step gradient of 30%, 50%, 
70%, 90%, and 100% MeOH in H2O).  Fractions Fr.4 (824 mg) and Fr.5 (156 mg) were 
combined (named Fr.7) and further separated into seven subfractions by preparative 
reversed-phase HPLC (eluted with linear gradient of 20% to 100% MeOH in H2O, 10.0 
mL min-1).  Subfraction Fr.7-5 was subjected to repeated semi-preparative reversed-
phase HPLC (isocratic 85% MeOH in H2O followed by 70% CH3CN in H2O, 4.0 
mL/min) to provide 5.1 (52.7 mg, 0.15% yield), 5.2 (5.4 mg, 0.015% yield), 5.3 (34.6 
mg, 0.098% yield), and 5.4 (2.4 mg, 0.0069% yield). 
5.4.3 Biofilm and growth inhibition assays with C. albicans 
The effects of mutanobactins on the growth of C.albicans DAY185 was tested 
using the methods prescribed in the CLSI guidelines.
116
  The biofilm inhibition assay 
was performed as described by Chandra et al.
117
 with the following modifications.  
Strain C. albicans DAY185 were cultured in BHI medium (Becton Dickinson, USA) at 
37 ºC overnight and were washed with sterile PBS buffer (pH 7.4, EMD Chemicals Inc., 
USA), and resuspended in RPMI 1640 medium (Sigma Chemical Corp., USA) buffered 
to pH 7.0 with MOPS (3-(N-morpholino)propanesulfonic acid, 0.165 M).  Test 
compounds were prepared in DMSO at a final concentration of 20 mM and were 










MOPS medium.  Farnesol was used as positive control.
118
  One hundred microliters of 
yeast suspension (2.5×10
3
 cells/mL) containing the diluted compounds (from 200 µM to 
6.25 µM) or DMSO (v/v 1%) were added to the wells of a 96-well microplate (Costar 
3370, Corning Inc., USA), and the plate incubated at 37 ºC.  After 48 h, the yeast 
viability was measured by XTT assay.
119
  In brief, yeast cells were treated with 
0.1mg/mL XTT at 37 ºC for 1 h.  The absorbance was taken at 490 nm using a 
microplate reader (Infinite M200, Tecan Group Ltd., Switzerland).  The minimum 
inhibitory concentration (MIC) for growth was defined as the lowest concentration that 
caused ≥80% reduction in the metabolic activity of the yeast.  After the XTT was 
completed, the spent medium was immediately aspirated from each well and the wells 
washed twice with sterile PBS to remove nonadherent cells.  Aliquots consisting of 100 
µL RPMI 1640 plus MOPS medium were then added to each well.  The washed 
biofilms were again measured using the XTT assay.  All experiments were performed in 
triplicate on three separate occasions.  The 50% inhibitory concentration (IC50) valuse 
for biofilm inhibition were calculated using GraphPad Prism software (GraphPad, USA). 
5.4.4 Feeding experiments with isotopically labeled acetate and amino acids 
For the isotope labeling experiments, 500 mg of [1-
13
C] or [2-13C] sodium 








N]Asp (Cambridge Isotope 
Laboratories, Inc., USA) was dissolved in water and filter sterilized.  The isotopes were 
added separately to 6 L of sterile BHI medium and culture vessels inoculated with an 
overnight culture of S. mutans.  Cultures were maintained at 37 ºC for 86 h at which 
time they were extracted with equal volumes of EtOAc (3×).  The extracts were each 
separated into three fractions over silica gel using an Isolera flash column (vide supra).  










semi-preparative HPLC to give approximately 5 mg of labeled 1 from each of the three 
cultures.  A 
13
C NMR spectrum was obtained at 100 MHz for each of the labeled 
compounds under identical experimental conditions. 
5.4.5 Mutanobactin B (5.2).   
White amorphous powder, [α]
21
D 24.4 (c 0. 27, MeOH); UV (MeOH) λmax (log 







data, see Table 5.1; HRESIMS m/z 757.4298 [M + Na]
+
 (calcd for 
C37H62N6O7SNa,757.4298). 
5.4.6 Mutanobactin C (5.3).  
White amorphous powder, [α]
21
D –3.7 (c 0. 38, MeOH); UV (MeOH) λmax (log 






C NMR data, 
see Table 5.1; HRESIMS m/z 743.4138 [M + Na]
+
 (calcd for C36H60N6O7SNa, 
743.4142). 
5.4.7 Mutanobactin D (5.4).   
White amorphous powder, [α]
21
D 18.3 (c 0. 12, MeOH); UV (MeOH) λmax (log 






C NMR data, see 
Table 5.1; HRESIMS m/z 743.4681 [M + Na]
+
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Table A1.  Crystal data and structure refinement for atlantinone A (3.9) 
 
Empirical formula (C26H34O6) (CH4O)  
 
C27H38O7  
Formula weight 474.57  
Crystal system Orthorhombic  
Space group P212121  
Unit cell dimensions 
 
 
a = 12.0199(6) Å = 90° 
b = 13.7713(6) Å = 90° 
c = 14.8276(8) Å = 90°  
Volume 2454.4[97] Å3  
Z, Z' 4, 1  
Density (calculated) 1.284 Mg/m3  
Wavelength 1.54178 Å  
Temperature 100[97] K  
F(000) 1024  
Absorption coefficient 0.746 mm-1  
Absorption correction 
equivalents  
Semi-empirical from  
 
Max. and min. transmission 0.832 and 0.694  
Theta range for data collection 4.38 to 69.53°  
Reflections collected 26979  
Independent reflections 4555 [R(int) = 0.0476]  
Data / restraints / parameters 4555 / 0 / 314  
wR(F2 all data) wR2 = 0.0802  
R(F obsd data) R1 = 0.0327  
Goodness-of-fit on F2 1.001  
Observed data [I > 2(I)] 4244  
Absolute structure parameter 0.01(14)  
Extinction coefficient 0.0040[97]  
Largest and mean shift / s.u. 0.000and 0.000  













Table A2. Crystal data and structure refinement for waikialoid A (4.7) 
 
Empirical formula  (C52 H54 N6O7) ∙ (H2 O) ∙ (C H4 O) 
 C53 H60 N6 O9 
Formula weight  925.07 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions  a = 10.6276(4) Å      α= 90° 
 b = 17.6706(6) Å      β= 104.187(2)° 
 c = 12.8917(4) Å      γ= 90° 
Volume 2347.17(14) Å3 
Z, Z' 2, 1 
Density (calculated) 1.309 Mg/m3 
Wavelength  1.54178 Å 
Temperature  100(2) K 
F(000) 984 
Absorption coefficient 0.731 mm-1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8418 and 0.6520 
Theta range for data collection 3.54 to 67.16° 
Reflections collected 67703 
Independent reflections 7859 [R(int) = 0.0272] 
Data / restraints / parameters 7859 / 21 / 635 
wR (F2 all data) wR2 = 0.0845 
R(F obsd data) R1 = 0.0316 
Goodness-of-fit on F2 1.005 
Observed data [I > 2σ(I)] 7855 
Absolute structure parameter 0.05(11) 
Largest and mean shift / s.u.                          0.033 and 0.001               













Table A3. Crystal data and structure refinement for asperonol A (4.15) 
 
Empirical formula  C14 H20 O2 
Formula weight  220.30 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions  a = 7.274(8) Å        α= 90° 
 b = 5.066(6) Å      β= 98.53[99]° 
 c = 17.43[97] Å      γ= 90° 
Volume 635.2(13) Å3 
Z, Z' 2,1 
Density (calculated) 1.152 Mg/m
3
  
Wavelength  0.71073 Å  
Temperature  100[97] K 
F(000) 240 
Absorption coefficient 0.075 mm
-1
 
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.9970 and 0.9613  
Theta range for data collection 2.36 to 22.99° 
Reflections collected 4287 
Independent reflections 1000 [R (int) = 0.1127] 
Data / restraints / parameters 1000 / 1 / 150  
wR(F2 all data) wR2 = 0.1720 
R(F obsd data) R1 = 0.0710 
Goodness-of-fit on F2 1.051 
Observed data [I > 2σ(I)] 730  
Absolute structure parameter -3(5) 
Largest and mean shift / s.u.                                          0.000and 0.000         
Largest diff. peak and hole 0.227 and -0.257 e/Å3 
Empirical formula  C14 H20 O2 
Formula weight  220.30 
Crystal system  Monoclinic 














C-NMR NMR data for mutanobactin A (5.1) (500 
and 100 MHz, DMSO-d6) – Shifts shown in red have been revised. 
position 
Mutanobactin A (5.1) (original)  Mutanobactin A (5.1) (revised) 
δC δH mult. (J in Hz)  δC δH mult. (J in Hz) 
1 50.4, CH 4.43 ddd (3.7, 9.0, 11.0)  50.4, CH 4.43 ddd (3.7, 9.0, 11.0) 
2a 40.4, CH2 1.44, m  40.4, CH2 1.44, m 
2b  1.81, ddd (3.9, 10.5, 13.8)   1.81, ddd (3.9, 10.5, 13.8) 
3 24.2, CH 1.59, m  24.2, CH 1.59, m 
4 20.9, CH3 0.82, d (6.6)  20.9, CH3 0.82, d (6.6) 
5 23.5, CH3 0.92, d (6.7)  23.5, CH3 0.92, d (6.7) 
6 170.5, C   170.5, C  
7 48.0, CH 4.52, q (6.8)  48.0, CH 4.52, q (6.8) 
8 17.7, CH3 1.17, d (6.7)  17.7, CH3 1.17, d (6.7) 
9 169.7, C   169.7, C  
10 61.0, CH 4.12, dd (3.7, 8.9)  61.0, CH 4.12, dd (3.7, 8.9) 
11a 29.6, CH2 1.72, m  29.6, CH2 1.72, m 
11b  2.13, m   2.13, m 
12 24.5, CH2 1.90, m  24.5, CH2 1.90, m 
13a 46.8, CH2 3.43, m  46.8, CH2 3.43, m 
13b  3.65, ddd (4.5, 7.5, 9.8)   3.65, ddd (4.5, 7.5, 9.8) 
14 171.6, C   171.6, C  
15 58.8, CH 3.57, dd (8.3, 10.0)  58.8, CH 3.57, dd (8.3, 10.0) 
16 26.2, CH 2.33, m  26.2, CH 2.33, m 
17 20.4, CH3 0.84, d (6.6)  20.4, CH3 0.84, d (6.6) 
18 18.8, CH3 0.77, d (6.8)  18.8, CH3 0.77, d (6.8) 
19 168.8, C   168.8, C  
20 52.2, CH 4.87 ddd (2.6, 8.0, 9.0)  52.2, CH 4.87 ddd (2.6, 8.0, 9.0) 
21a 28.5, CH2 2.23, dd (2.6, 16.0)  28.4, CH2 2.23, dd (2.6, 16.0) 
21b  3.19, dd (9.0, 16.0)   3.19, dd (9.0, 16.0) 
22 170.4, C   170.4, C  
23a 43.7, CH2 2.79, m  43.7, CH2 2.79, m 
23b  3.28, m   3.28, m 
24 41.0, CH 3.25, m  41.0, CH 3.25, m 
25 61.7, CH 3.87, d (9.8)  61.7, CH 3.87, d (9.8) 
26 167.7, C   167.7, C  
27 203.8, C   203.8, C  
28a 41.4, CH2 2.33, m  41.4, CH2 2.33, m 
28b  2.44, dd (6.0, 16.6)   2.44, dd (6.0, 16.6) 
29 23.1, CH2 1.44, m  23.1, CH2 1.44, m 
30 28.7, CH2 1.20, m  28.5, CH2 1.20, m 
31 22.1, CH2 1.25, m  28.7, CH2 1.25, m 
32 28.8, CH2 1.23, m  28.9, CH2 1.27, m 
33 22.1, CH2 1.25, m  28.8, CH2 1.23, m 
34 31.3, CH2 1.23, m  31.3, CH2 1.23, m 
35 28.9, CH2 1.27, m  22.1, CH2 1.25, m 
36 14.0, CH3 0.85, t (6.8)  14.0, CH3 0.85, t (6.8) 
C1-NH  8.59, d (9.0)   8.59, d (9.0) 
C7-NH  7.77, d (6.5)   7.77, d (6.5) 
C15-NH  8.05, d (8.5)   8.05, d (8.5) 
C20-NH  7.23, d (8.0)   7.23, d (8.0) 





















































Figure A2. Effects of compounds 4.7 and 4.15 on Candida albicans hyphae formation. 
C.albicans DAY185 cells were treated with DMSO as negative control, farnesol as 
positive control, compound 4.7 and 4.15 for 6 h. Cell morphology was visualized at 2.5, 













Figure A3. Time of addition assay of compound 4.7. Compound 4.7 (25 µM) was 
added before (-0.5 h) or at 0, 2, 4, 6, 8 and 24 h after seeding to C. albicans DAY185 
culture in a 96-well microplate. At 48 h after seeding, the wells were washed by PBS 
twice and the amount of biofilm formation in the wells was determined using XTT 














Figure A4. HPLC analysis of FDAA derivatized hydrolysate mutanobactin B-D (5.2-
5.4) and amino acid standards. (Gradient elution: 30-60% MeCN, 40mins) 
 


















































































































































Mutanobactin B (5.2)  
 
Mutanobactin C (5.3)  
 
Mutanobactin D (5.4)  
 















Figure A5. HPLC analysis of FDAA derivatized hydrolysate mutanobactin D and α -






































































L-Abu standard   




































































HMBC-NMR spectrum (500 MHz, CDCl3) of atlantinone A (3.9b)      











































































HMBC-NMR spectrum (500 MHz, CD3OD) of atlantinone A (3.9a) 
 
 





















































































































































































































































































































































































































































































CD spectrum of asperonol A (4.15) 

































C-NMR spectrum (100 MHz, CD3OD) asperonol B (4.16) 
 











































































































































































































































C-NMR spectrum (100 MHz, DMSO-d6) of mutanobactin A-[1-
13













































NOESY-NMR spectrum (500 MHz, DMSO-d6) of mutanobactin A (5.1)
 
